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Pharmacokinetic/pharmacodynamic (PKPD) modelling seeks to
quantify the dose–concentration–effect relationship with a mathemati-
cal model. It can be used in both pre-clinical and clinical study designs.
The statistical aspect to PKPD modelling seeks to quantify variability in
the data, and following suitable evaluation, simulate the predicted be-
haviour of the system. This so-called pharmacometric approach is in-
creasingly recognised as being an important supplement to randomised
control trial (RCT) data [1], particularly in patient groups where recruit-
ment to RCTs is problematic, such as in children and neonates.
Duringmodel development, when ﬁtting a PKPDmodel to data from
in vitro and/or in vivo sources, there will always be some element of
‘noise’ whereby the model does not ﬁt the exact data points, since by
deﬁnition amathematical model is a simpliﬁcation of reality. Themath-
ematical PKPDmodel is therefore extended to include a statistical com-
ponent which models this noise; typically the central tendency of the
noise is assumed to have a mean of zero (so that model predictions go
through the middle of the data) and the noise magnitude (its variance)
is estimated. Typical uses of a PKPD model are to make inferences on
whether and to what extent a drug's dose and concentrations are asso-
ciated with markers of disease or disease resolution.
One difﬁculty in properly conducting clinical PKPD studies is the fact
that the experimental units (patients) are not homogenous. For this
reason, care is needed when modelling data from more than one
subject, because it is known a priori that individuals differ from one an-
other; this is true for both PK and PD outcomes. Indeed, ﬁtting a single
model to all data (the naïve pooled or data averaging approach), and
to a lesser extent ﬁtting the model to each individual and then averag-
ing parameter estimates (two-stage approach) are methods known to
bias parameter estimates [2]. Fortunately, over the past 30 years clinical
pharmacology has been at the forefront of implementing the so-called
‘population approach’ using the statistical method known as non-
linear mixed effects (NLME) modelling. By ﬁtting a single model to all
individuals simultaneously, whilst allowing for two levels of random ef-
fects (noise), estimates can be made of both the model parameter typ-
ical values and their inter-individual variability, in addition to the
residual variability. By splitting the variability in this way, and so
allowing model parameters to take different values in each individual,
unbiased estimates can be obtained. A further beneﬁt is that by taking
this population-level approach, individual subjects can contribute dif-
fering amounts of data, making opportunistic sampling designs a possi-
bility. An introduction to the ﬁeld of population PKPD modelling is
described elsewhere [2–7].
For themajority of antimicrobial agents there tends to be some pub-
lished PK which, although may not cover all paediatric age groups, is
usually sufﬁcient to predict paediatric PK across ages using knowledge
of developmental differences [8]. Knowledge of PK alone is, however,
insufﬁcient to deﬁne a dose recommendation. In order to develop guid-
ance on dosing, the dose-concentration-effect relationship needs to be
understood and this means going beyond PK, to make extrapolations
as to how these concentrations link with effect (PD). There are two
main approaches thatmake the link from PK to PD in infectious diseasesresearch. The most common approach uses simulations from the PK
model to determine a dose which yields a pre-deﬁned endpoint,
which is thought to translate to the desired effect. Such endpoints are
often derived from in vitro concentration-effect experiments [9], al-
though in vivo animal PKPD outcomes or previous clinical PKPD studies
can be used [10]. Amajor disadvantage of this approach is that assump-
tions have to bemade about factors such as the circulating drug concen-
tration being proportional to that at the site of pathogen load, or the
transferability of outcomes between different studies. The second, and
more challenging approach, is to collect and model both PK and PD
information in the same patient, thereby eliminating the need for ex-
trapolations. Whilst the data generated from this approach could be
considered gold standard, the difﬁculty lies in deﬁning a suitable PD
endpoint, recruiting patients to such studies (e.g. many neonates
treatedwith antimicrobials do not have proven infection) and obtaining
stable estimates of a joint PKPD model. This review is focused on
summarising the PKPD information available in paediatric infectious
diseases and immunology, the modelling approaches taken, and identi-
fying potential avenues for future PKPD research. The PubMed database
search terms included the generic drug names and classes of antimicro-
bials, pharmacokinetics, pharmacodynamics, paediatric/pediatric and
neonatal, and disease states where relevant: titles and abstracts of pa-
pers available in English were reviewed, and selected for inclusion if
they contained relevant or new information.
2. Infectious diseases
2.1. Bacterial infections
The PKPD indices of most antibacterial agents have been deﬁned
from both in vitro and animal and human in vivo studies. A summary
of these is given in Table 1. Typically a breakpoint for susceptibility
will be set based on the minimum inhibitory concentration (MIC) of
the antibacterial, that is to say theminimal concentration required to in-
hibit growth in strains considered sensitive. This breakpoint is then
compared to either circulating maximum (Cmax) concentrations, area
under the curve (AUC), or circulating time aboveMIC (TNMIC) depend-
ing on the antibacterial mode of action.
2.1.1. Beta-lactam antibiotics
The beta-lactam agents act principally by causing irreversible inhibi-
tion of bacterial cell wall synthesis, achieved by covalent binding to
penicillin-binding proteins [11,12]. Beta-lactams are renally cleared,
and have a wide therapeutic index [13]. On the basis of in vitro and
in vivo data, the pharmacodynamic target for beta-lactam therapy is
the fraction of time per dosing interval that the free drug concentration
exceeds the minimum inhibitory concentration (MIC) of the organism
(denoted by %TNMIC) [14]. This is thought to be due to the fact that
the penicillin binding protein requires near saturation before cytotoxic-
ity occurs, implying that theminimum concentration required for effect
is close to the maximum possible effect. The standard therapeutic goal
for penicillins is %TNMIC of 30–40% which has generally been derived
from observing that this value leads to decrease in bacterial load either
Table 1
PKPD indices for major classes of antibacterial agents.
Pharmacodynamics Class of antibacterial Speciﬁc drug (where applicable) PD parameter PD target of therapy
Time-dependent Beta-lactams – %TNMIC [9] Max %T in the dosing interval NMIC
Macrolides Conventional macrolides %TNMIC [192] Max %T in the dosing interval NMIC
Azithromycin AUC/MIC [9] Optimal daily amount
Glycopeptides – AUC/MIC [57] Optimal daily amount
Tetracyclines – AUC/MIC [191] Optimal daily amount
Oxazolidinones Conventional oxazolidinones %TNMIC [192] Max %T in the dosing interval NMIC
Linezolid AUC/MIC [191] Optimal daily amount
Concentration-dependent Aminoglycosides – Cmax/MIC or AUC/MIC [10] Max peak concentration or optimal daily amount
(Fluoro)quinolones – Cmax/MIC or AUC/MIC [66] Max peak concentration or optimal daily amount
Metronidazole – Cmax/MIC or AUC/MIC [192] Max peak concentration or optimal daily amount
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though neonates are considered functionally immunocompromised
and so 40–50% or more is often recommended [16].
2.1.1.1. Penicillins. Neonatal studies on benzylpenicillin (penicillin G)
[17], intravenous ﬂucloxacillin [18], intravenous amoxicillin [19,20]
and piperacillin/tazobactam [21] have been conducted, each of which
involved estimating the parameters of a population PK model and
using them to simulate dosing regimens that attain in vitro-derived cir-
culating %TNMIC values.
Another approach to deﬁning dose regimens can be seen with the
example of ticarcillin/clavulanate in paediatric cystic ﬁbrosis (CF) pa-
tients who received high-dose intermittent ticarcillin-clavulanate
(above the maximum dose approved by the FDA (United States Food
and Drug Administration) [22]. The authors had PD data and obtained
PK parameter estimates for intravenous ticarcillin in children and adults
with CF from the literature [23], whichwere used to simulate serum free
drug concentrations.
No paediatric penicillin studywas foundwhich usedmicrobiological
or clinical PD outcomes observed in the patients undergoing PK sam-
pling, and so it would appear that dosing guidelines for these agents
are exclusively based on simulations or even simple extrapolations to
reach PD targets derived in adult and in vitro studies. The use of differ-
ent PD targets and breakpoints between studies is notable; importantly,
some breakpoints have since changed (such as the piperacillin
breakpoint for Pseudomonas) [24,25], and will be expected to increase
further as increasing antimicrobial resistance is encountered.
2.1.1.2. Cephalosporins. A PK study on cefuroxime was undertaken in 15
paediatric cardiovascular surgery patients undergoing cardiopulmonary
bypass who received prophylaxis against surgical site infection [26].
Simulations were used to compare two dosing regimens; single and
double dose. Both regimens were found to result in a free drug concen-
tration exceeding the MIC value for staphylococcal species of 8 μg/mL
(taken from the literature) for the whole dosing interval, so therefore
there was no beneﬁt in a second dose.
Ceftriaxone was studied using published serum concentrations of
ceftriaxone from 78 Japanese paediatric patients from 8 previous stud-
ies; simulation was then used to assess %TNMIC in different dosing reg-
imens [27]. The PD target of %TNMIC used MICs for several pathogens
taken from the literature and the analysis suggested that a once daily
dosing regimen (of 20 mg/kg) was appropriate in most cases.
The PK of cefotaxime and its active metabolite, desacetylcefotaxime
(DACT), were estimated in a study of 37 neonates on extracorporeal
membrane oxygenation (ECMO) [28]. It is known that ECMO may
alter drug disposition in variousways, for example by increasing the ap-
parent volume of distribution, or by reducing drug clearance [29]. In the
neonatal cefotaxime study the PD target was set at N50%TNMIC, and
using MIC values from the literature for pathogens that may cause neo-
natal meningitis, with consideration of drug protein binding, simulated
concentration-time curves were constructed for each individual.Aswith the penicillins, a heavy reliance on linking circulating in vitro
derived breakpoints has been used to deﬁne cephalosporin dose
recommendations.
2.1.1.3. Carbapenems. There have been several population PK studies of
meropenem involving neonates, infants and/or children [30–37]. A pop-
ulation PK study was conducted in 37 infants following a single dose of
meropenem (10 or 20 mg/kg) [30]. Simulation was then used to evalu-
ate the PD target attainment of %TNMIC ≥ 60%, using MIC distributions
for relevant common pathogens. In another study, neonates were ran-
domly allocated to receive a single intravenous dose of 10, 20, or
40 mg/kg [33]. Simulationwas used to estimate probability of target at-
tainment with different doses, infusion durations and dose intervals,
usingMIC values from the literature. Theﬁnal neonatal study investigat-
ed the impact of short versus long infusion duration of meropenem in
19 very-low-birth-weight neonates [35]. While shorter infusions gave
a higher Cmax, the %TNMIC was higher with prolonged infusions.
Meropenem plasma and cerebrospinal ﬂuid (CSF) PK were investi-
gated in a study of 188 infants with suspected/complicated intra-
abdominal infections using sparse sampling [37]. The PD targets were
N4 μg/mL for 50% of the dose interval and N2 μg/mL for 75% of the
dose interval, chosen due to the reduced immunocompetence of neo-
nates. CSF was obtained from 6 participants, but the reported 70% pen-
etration of meropenem into the CSF was erroneous since CSF:plasma
ratio was calculated rather than AUCCSF:AUCplasma [37]. Two further
studies in children developed a population PK model and then used
simulation to recommend an optimal infusion length [34] or absolute
dose [32] for infections with common bacteria without further specify-
ing an indication.
The only meropenem study to link PK with PD in the recruited pa-
tients used data from 99 individuals to develop a population PK model
[31]. The validated model was used for simulation to predict
meropenemplasma concentrations in 37 paediatricmeningitis patients,
following 40 mg/kg meropenem, with MICs of the causative bacteria
known. The causative pathogens were eradicated in all cases, so no
break points were identiﬁed.
A paediatric population PK imipenem meta-analysis in NONMEM
has recently been undertaken using pooled individual patient data
from 15 previous studies [38]. The dataset included PK samples from
60 neonates and 39 children. The PD target was 40%TNMIC, using MIC
distributions from the literature for 5 common pathogens. Simulations
were conducted to assess the probability of target attainment with dif-
ferent doses and infusion lengths.
In summary the population PK of the carbapenems have been com-
prehensively studied in children, with dose recommendations largely
being derived by simulation to attain an in vitro derived target.
2.1.2. Aminoglycosides
Aminoglycosides exhibit antibacterial activity by binding to the ribo-
some and interrupting protein synthesis. This intra-cellular mode of ac-
tion is the reason for the observed post-antibiotic effect, whereby
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have fallen to low levels. Furthermore, many pathogens exhibit amino-
glycoside adaptive resistance whereby the transporters responsible for
internalising the drug are transiently down-regulated [39,40]. Thus
the PD target for aminoglycosides is high peak relative to the MIC (to
penetrate the bacteria) and low trough (to provide a drug-free period
and minimise adaptive resistance and toxicity), and this strategy has
been shown to correlate with clinical response in adults (Fig. 1) [10].
Several population PK studies have been conducted on gentamicin
in children of different ages, with dose recommendations usually
being made using simulation [41–46]. A recent paper by Mohamed
et al. has sought to use in vitro data tomore fully investigate gentamicin
PD by developing a semi-mechanistic PKPDmodel [47]. In vitro experi-
ments using E. coli (withMIC of 2mg/L) were performed in order to de-
ﬁne the time-kill curve. In order to characterise amodel that would take
into account the development of adaptive resistance, two compart-
ments were deﬁned: one for drug-susceptible, growing bacteria, and
the other for insusceptible, resting bacteria. They found that when de-
scribing the killing effect of gentamicin, a saturable logistic Emax model
was signiﬁcantly better than a linearmodel. Adaptive resistancewas in-
corporated in the model by using a binding function. When gentamicin
was present and thus adaptive resistance could develop, the binding
function reduced Emax and resulted in lower killing rates. It was also
found that the half-life of the development of adaptive resistance is
concentration-dependent, and it takes longer to develop at lower drug
concentrations. In this study the rate of returning to susceptibility was
ﬁxed (to 50 h, the lowest value that did not reduce the ﬁt of the
model) due to uninformative data. The estimated maximal killing rate
of 51/h conﬁrmed the fast bactericidal effect of gentamicin. It was also
found that even though the dosing regimen 4 mg/kg every 24 h pro-
duces lower peaks in preterm neonates, the bactericidal effect may be
sufﬁcient. By linking dynamic in vitro experimentswith rigorous clinical
PK data, this study may point to a better way of incorporating PD data
when making dosing recommendations in situations where clinical PD
data are difﬁcult to obtain.
Amikacin PK has also been extensively studied in children [48–50],
and one of these by Sherwin et al. did attempt to incorporate clinical
PD endpoints [51]. This retrospective study included 80 neonates, 26
ofwhomhad 35 conﬁrmed septic episodes between them. A population
PK model was developed and the PDwas a logistic regression approach
with a dichotomous outcome i.e. success/failure of the treatment. It was
found that therapeutic failure depends only on amikacin peak concen-
tration/MIC ratio.
Tobramycin is frequently used for treatment of pulmonary infections
in CF, as it is highly effective against Pseudomonas aeruginosa. Several PK
studies have been published in children without attempting to model
PKPD relationships within the included patients [52–55]. One study
looked at all the aminoglycosides in 45 HIV-infected children andFig. 1. Relationship found by Moore et al. relating clinical response to Cmax:MIC ratio of
aminoglycosides in a meta-analysis of adult studies [10].reported whether peak concentrations reached a target level for the
given dosage regime [56].
Overall the aminoglycosides have been the focus of numerous PK
studies, which is probably the result of them being the subject of thera-
peutic drug monitoring (TDM) due to a narrow therapeutic index. PD
modelling has focussed on efﬁcacy and some particularly interesting
work on integrating dynamic in vitro data has been done [47], but no
studies that we found investigated the PKPD relationship with the de-
velopment of nephrotoxicity (except some animal studies [57] and re-
views [58] that linked aminoglycoside dose with nephrotoxicity); this
may become increasingly important to understand, as the pressure to
increase doses to meet rising pathogen MICs continues.
2.1.3. Glycopeptides
Glycopeptides bind to alanine during bacterial cell wall synthesis
thus interrupting this process by preventing the membranes cross-
linking. The dynamics of this effect are timedependent and the relation-
ship between dose and effect is best characterised by AUC:MIC ratio
[59]. Several studies have investigated the PK of vancomycin (mainly
in neonates and infants) [60–64] and also teicoplanin [65–67]. Howev-
er, the PD link in these studies has been through simulations to achieve
target concentrations rather than looking at the PD in the included
subjects.
2.1.4. Quinolones
Quinolone antibiotics inhibit DNA gyrase and, in common with the
aminoglycosides, this would suggest that peak:MIC ratio would be the
key PD endpoint. During the development of levoﬂoxacin, which re-
mains a gold standard against which other clinical antimicrobial studies
ought to be measured, the peak:MIC ratio at the site of infection was
shown to correlate with clinical response in adults [68]. The use of quin-
olones in children has been limited due to fears of the potential to cause
cartilage damage, as demonstrated in a study where Beagle dogs devel-
oped arthropathy after ciproﬂoxacin administration [69].
Despite this, quinolones are increasingly used in children, and popu-
lation PK studies of ciproﬂoxacin have been published [70–72]. No
linked PKPD studies have yet been performed in paediatric patients to
reﬂect the seminal adult papers by Ambrose et al. [73] and Forrest
et al. [74], which supported the use of AUC/MIC ratio as the most clini-
cally relevant PD target. However, further PKPD studies will be required
to verify which PKPD index is most suitable for targeting quinolone
therapy in children.
2.1.5. Macrolides
One population-PK study involving macrolides has been conducted,
focusing on the PK of single-dose azithromycin in 12 preterm neonates
at risk of Ureaplasma colonisation [75]. The pharmacodynamic target
was to maintain azithromycin plasma concentrations above the MIC50
(1 μg/mL); this value was obtained from Ureaplasma isolates from 25
neonates at the local institution. A single dose (10 mg/kg/day) ormulti-
ple doses of this amount was simulated to achieve this target.
2.1.6. Other antibacterial agents
Metronidazole is used to treat anaerobic infections and has an intra-
cellular mechanism of action. Recently there have been studies looking
at the population PK of metronidazole in neonates, and dose recom-
mendationshave beenmadebased on checkingwhether the predeﬁned
PD targets (steady-state plasma concentration of metronidazoleNMIC of
anaerobic microorganism) were met [76–78], and whether there were
any anaerobic infections present or not [76]. A lack of clarity on optimal
metronidazole PKPD endpointsmeans that there is a need to obtain fur-
ther clinical dose–response data in children.
Linezolid is a synthetic antibiotic of the oxazolidinone class, effective
against Gram-negative microorganisms. The PD target for linezolid is a
maximised ratio of AUC:MIC [191]. To our knowledge there are no
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compartmental PK analysis [79].
2.2. Fungal infections
2.2.1. Azoles
The azole antifungals inhibit ergosterol synthesis in the fungal cell
wall. Clinical data on resolution of Candida infection with measured
MIC values regressed against typical exposures for dose showed AUC:
MIC ratio to predict effect in adults [80]. Azole antifungals appear to dis-
play post antimicrobial effects whereby cytotoxic effects continue even
once concentrations have fallen below the MIC [81].
The dose recommendations of ﬂuconazole in neonates are based on
preliminary PK studies that suggested a dose of 6 mg/kg daily results in
serum concentrations that were above the MIC of Candida parapsilosis
72 h post dose [82]. Clearance of ﬂuconazole rises with gestational
age, approximately doubling in the ﬁrst 4 weeks of life, meaning
prolonged dosing intervals (i.e. 48–72 h) are often used in clinical prac-
tice [83,84]. In the treatment of invasive candidiasis, a higher neonatal
dosage of 12 mg/kg daily in neonates b29 weeks gestation results in a
median AUC of ~700 mg/L h (which approach drug exposures required
for successful treatment in animals studies) [85]. Loading doses enable
AUC:MIC targets to be achieved rapidly [86]. TDM for ﬂuconazole is
not generally performed, but assays are available and some have argued
it may be beneﬁcial particularly in the neonatal population [87]. No
linked PKPD or modelling studies have been carried out to inform ﬂu-
conazole dosing in infants and older children. The pharmacokinetics ap-
pear linear, with a dosage of 8 mg/kg daily producing an AUC of
~200 mg/L h, which is comparable to an average adult receiving a
dose of 200 mg daily [88]. Higher exposures are usually required for
the treatment of disseminated candidiasis in adults, suggesting that
8 mg/kg may be inadequate in children, especially against organisms
with reduced susceptibility.
Itraconazole is available in a capsular form, a cyclodextrin-based oral
solution, and an intravenous preparation (not widely available in the
U.S. or Europe). Doses of 2.5-5.0 mg/kg daily have been used with ap-
parent efﬁcacy [89–92]; however, there are no PKPD studies available
to guide dosing. Limited data suggest the PK of itraconazole are non-
linear and highly variable, and that weight-based dosing leads to sub-
therapeutic dosing in smaller children [93,94]. When itraconazole is
used, TDM is generally advocated with a target trough levels of
N0.5mg/L (usingHPLC) and 5–17mg/L (using bioassay) are extrapolat-
ed from studies in adults [95–97].
Voriconazole is, at present, infrequently used in neonates, its main
use being in the treatment of invasive aspergillosis and in ﬂuconazole-
resistant candidiasis [98–100]. Extreme variability in serum concentra-
tions is apparent, with no clear relationship between drug exposure and
weight-based dosages [99]. Voriconazole PK in older children and adults
is characterised by signiﬁcant variability in concentration–time proﬁles
and non-linear clearance [101]. Population PK models ﬁtted to paediat-
ric datasets have been used to deﬁne regimens for intravenous
voriconazole that produce drug exposures comparable with those
seen in adults [102]. Population PK analyses have consistently identiﬁed
considerable PK variability in children, usually making dosing recom-
mendations based on simulation to achieve adult exposures, and pro-
viding the basis for TDM [103–107]. A trough concentration target of
1–5 mg/L is used in adults receiving voriconazole [108]. In children,
trough plasma concentrations b1mg/L are associatedwith higher prob-
ability of death and extrapolation of the adult upper boundary of 5mg/L
to paediatric populations is disputed given the lack of hepatotoxicity
seen in children [103,106]. One population PK model has attempted to
provide TDM guidance by showing that an increase in dose of 1 mg/kg
results in an increase in the median trough concentrations by 0.5 mg/L
[106].
Posaconazole is only currently available as an oral suspension, and is
only licenced for use in children over twelve years. No studies werefound that examine posaconazole PK linkedwith PD in children. Twelve
children aged 8–17 years receiving posaconazole 800mg daily in divid-
ed doses hadmean serum concentrations and clinical outcomes compa-
rable with adults [109]. Further studies are required to deﬁne
appropriate regimens for posaconazole use in children.
2.2.2. Echinocandins
Echinocandins inhibit fungal cell wall synthesis and have activity
against Candida and Aspergillus species. This concentration-dependent
effect has translated into the PKPD target being circulating Cmax:MIC
ratio or tissue AUC:MIC ratiowhich have been deﬁned in animalmodels
[110]. Echinocandins display an apparent post-antimicrobial effect,
which is probably due to tissue accumulationof thedrug resulting in an-
tifungal activity after plasma concentrations have fallen [110].
The pharmacokinetics of caspofungin have been described in 18 ne-
onates and mean peak and trough concentrations were compared to
adults receiving 50 mg, although clinical efﬁcacy was not described
[111]. In 39 neutropenic children receiving antifungal prophylaxis,
daily doses of 1 mg/kg daily resulted in signiﬁcantly lower drug
exposures than those observed in adults receiving a standard 50 mg
daily. Surface area-adjusted dosing (70 mg/m2 loading followed by
50 mg/m2 maintenance) resulted in drug exposures more comparable
with adults [112,113]. No linked PKPD modelling studies were found
for caspofungin.
Micafungin has been studied in a dose-ranging study on neonates
using population PK modelling; this study identiﬁed an optimal dose
of 10 mg/kg daily, which resulted in AUCs approaching near maximal
clearance of the fungal burden within the CNS (an important target tis-
sue compartment in this age) [114]. Population PK modelling of
micafungin in older children showed doses of 2 mg/kg achieve compa-
rable exposure with adults [115,116].
There are few data for PKPD of anidulafungin in neonates and chil-
dren. The drug has a unique mechanism of clearance, whereby the par-
ent compound undergoes spontaneous non-enzymatic hydrolysis. In
neutropenic children aged 2–17 years dosages of 0.75 and 1.5 mg/kg
daily resulted in drug exposures that are comparablewith adults receiv-
ing 50 and 100 mg daily, respectively [117,118].
2.2.3. Polyene antimycotics
Amphotericin B is the only systemically available polyene, which
binds to ergosterol causing membrane depolarisation and giving a
broad spectrum of activity against the majority of pathogenic yeasts
and moulds. Solubilisation of amphotericin B for parenteral adminis-
tration was initially achieved using the bile salt deoxycholate
(amphotericin B deoxycholate) and subsequently by incorporation
into various lipid formulations (e.g. amphotericin B lipid complex
and liposomal amphotericin B). The PKPD proﬁles of each of these
formulations are distinct and remain relatively poorly understood,
particularly in children. The pharmacokinetics of amphotericin B
deoxycholate are highly variable in neonates, and this may lead to
treatment failure or toxicity. Amphotericin B doses of 0.25–1 mg/kg ad-
ministered daily to infants results in lower serum concentrations com-
pared with larger children and adults [119,120]. Thirteen premature
neonates treated for invasive C. albicans infection with this dosing
range had peak unbound drug concentrations below reported MIC
values in 25% of cases, resulting in death attributed to fungal sepsis in
two cases. Correlations between clinical outcomes, serum levels and
pre-deﬁned MIC targets have not, however, been studied in larger co-
horts of neonates or children [121].
The various lipid formulations of amphotericin B are increasingly
used in place of amphotericin B deoxycholate, predominantly because
of their more favourable toxicity proﬁles. Liposomal amphotericin B
and amphotericin B lipid complex (ABLC) are the most commonly
used compounds in the U.S. and Europe. Despite extensive information
on clinical usage and safety, the PK of these compounds are poorly un-
derstood in neonates and children. PK modelling of data describing 28
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ment of invasive candidiasis [122]. Population PK modelling of liposo-
mal amphotericin B has been used to describe data from 39 children
with haematological malignancy. These analyses suggest that doses of
4 and 7.5 mg/kg daily achieve drug exposures that exceed target MIC
values for Candida and Aspergillus species, respectively. Children
b10 kg probably required higher doses, although these have not been
deﬁned [123]. Pharmacokinetic studies that enable equivalence of
drug exposure with these formulations to be established are urgently
required.
2.3. Viral infections
Whilst bacteria in particular present potential drug targets that are
usually quite distinct from host substrates, viral replication relies on
the sequestration of host cell machinery, and all infections have an
intra-cellular component, which bothmake developing effective antivi-
ral therapies more difﬁcult. Due to this, antivirals tend to have a
narrower therapeutic index than antibacterials, which provides a com-
pelling case for using PKPD modelling to optimise dosing. Antiviral
agents generally utilise the following mechanisms: interrupting viral
nucleic acid replication, inhibiting attachment to host cells and viral
entry, or blocking viral un-coating once in the cell. A comprehensive re-
view of antiviral (and antiretroviral) pharmacology and PK available for
children is given by Kimberlin [124].
2.3.1. Nucleoside and nucleotide analogues
Aciclovir is a purine nucleoside which is selectively phosphorylated
by viral thymidine kinase; subsequently, the active aciclovir triphos-
phate preferentially inhibits viral DNA polymerase. Due to its low oral
bioavailability, a prodrug of aciclovir called valaciclovir has been devel-
oped. Valaciclovir undergoes conversion to aciclovir during ﬁrst-pass
metabolism, thus enhancing bioavailability.
The PK of aciclovir have been extensively studied in children, and in
many cases an attempt to link circulating concentrations, either mea-
sured or predicted from a model, has been made. In one of the earliest
published PK studies, dose escalation of intravenous aciclovir (5, 10
and 15 mg/kg) was performed in neonates infected with herpes virus,
and measured PK was compared against in vitro IC50 values [125]. A
more sophisticated approach was taken by Sullender et al. [126], who
used simulation (without accounting for uncertainty) from a model
built to describe thePKof an oral aciclovir suspension to show that intra-
venous dosingwould be required to achieve target IC50 values although
full details on the in vitromethods and PD endpoints are lacking in these
studies. Three further studies reported PKmetrics [127–129] and linked
them to a measure of clinical outcomes (e.g. clinical response: yes/no
[127]) in the included patients, but did not then go on to attempt to
model this relationship.
The ﬁrst population PK study to implement an NLME approach was
published by Tod et al. in 2001 [130]. This large study in 102 neonates
and infants developed dosing guidelines based on achieving time great-
er than in vitro IC50 values by simulating from the PK model. More re-
cent population PK modelling has looked at bioavailability differences
between aciclovir and valaciclovir in children [131], and again the
linking to PD has been done using simulation and comparison with
in vitro inhibition data [132].
Penciclovir and its oral prodrug famciclovir have a similar spectrum
of activity to aciclovir; both non-compartmental [133,134] and popula-
tion PK models [135] have been published in children, but none have
sought to model the link between PK and PD endpoints.
Ganciclovir is a guanine analogue with inhibitory activity against
human herpes viruses. It has been used in childrenmainly for cytomeg-
alovirus (CMV) infections which are not susceptible to aciclovir due to
the lack of expression of the unique thymidine kinase. Possibly due to
its use against more serious infections, there are more PKPD studies in-
volving ganciclovir and its oral prodrug valganciclovir in children.Several studies have used both traditional and population PKmodel-
ling to describe ganciclovir and valganciclovir concentrations and then
link these with in vitro-derived targets or clinical response in an at-
tempt to deﬁne a suitable dose [136–141]. The problem with this ap-
proach was highlighted by Veniza et al. [142], who showed that out of
eight patients with measured ganciclovir concentrations (following
oral valganciclovir administration) which exceeded the in vitro IC50
for Epstein Barr Virus (EBV), four of them did not experience viral sup-
pression. This hints at the problem outlined by Luck et al. that the target
circulating concentration for ganciclovir is often unknown, and further
understanding of PKPD relationships is required [143].
In 36 HIV-infected children with CMV infection, oral ganciclovir PK
was deﬁned in ascending doses by a non-compartmental approach
and followed up over up to 168 weeks with CMV being qualitatively
analysed and tested for susceptibility [144]. A study on congenital
CMV infection looked at intravenous ganciclovir and oral valganciclovir
pharmacokinetics and their link with viral load over a 42 week treat-
ment course [145]. This study looked at the change of viral load from
baseline, showing that antiviral therapy signiﬁcantly reduced viral
load especially in patients with higher baseline, although the authors
did not develop a full linked PKPD model for this relationship. Many of
the ganciclovir and valganciclovir studies reported haematological tox-
icities, in particular neutropenia, and further work on this by modelling
the PKPD link between ganciclovir PK and neutrophil count may point
the way to deﬁning a maximum tolerable dose.
Ribavirin is a structural analogue of guanosine and has a broad spec-
trumof antiviral activity. Several studies have characterised the PK of ri-
bavirin in children via inhaled, intravenous and oral routes, although no
model for both PK and PD has been presented [146–149]. Finally, in this
group of agents, the nucleotide analogue cidofovir is used in children for
indications such as ganciclovir-resistant CMV, but again no linked PKPD
studies have been published in this population.
2.3.2. Interferons
Interferons induce the production of a family of proteins that inhibit
viral protein synthesis, cause viral RNA deactivation, and can enhance
phagocytosis, therefore providing broad non-speciﬁc antiviral effects.
Interferon-alpha is commonly used in combination with oral ribavirin
for the treatment of hepatitis C virus (HCV). One PKPD study investigat-
ed the combination of interferon-alpha and ribavirin in children with
chronic HCV infection [150]. This studymeasured detailed PD outcomes
including quantitative PCR for viral loads, but did not model their time
course. There is increasing interest in ﬁtting data of this type to mecha-
nistic PD models, which can then be used to extrapolate the combina-
tion of dose and course length required to suppress or cure the infection.
2.3.3. Neuraminidase inhibitors
The neuraminidase inhibitors are used to counter inﬂuenza A and B
through blockage of viral entry into host cells, as well as inhibiting the
release of new virions [151]. A detailed review of oseltamivir PKPD
data in children found that dosing guidelines were mainly based on ex-
trapolations of circulating PK to in vitro inhibitory concentrations [152],
although recent data on PK and inﬂuenza viral loads, and the develop-
ment of resistance, may in the future yield a PKPD model [153]. No
PKPD studies for zanamivir or laninamivir were found, but a large
study including 117 children receiving peramivir did not ﬁnd a link be-
tween AUC or Cmax versus markers of infection resolution, although this
was not done with a joint PKPD approach [154].
3. Immunology
3.1. PKPD modelling in HIV infection
The PK ofmost commonly used antiretrovirals have been studied in-
dividually in children. Howbest to link these PK datawith important PD
markers is only gradually becoming clear, as combination therapy
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Fig. 2.Model for HIV-T-cell dynamics model proposed by Perelson et al. [156]. The num-
bers of uninfected CD4+ T-cells were assumed to remain constant throughout (grey
box). Outlined boxes indicate quantities modelled by differential equations; solid arrows
represent ﬁrst-order rate constants, and the dashed arrow indicates the effect of viral
load on the infection rate. Before ART, all new virions produced are infectious. T-cells are
infected at a rate proportional to the number of infectious virions, kVI, die at rate δ and pro-
duce new virus at rate Nδ (i.e. N new virions per cell death). Virus is cleared at rate c. On
ART, all newly produced virions are non-infectious. As infectious virus is cleared the T-cell
infection rate decreases, numbers of infected T-cells fall and fewer new HIV particles are
produced. The reducing viral production rate combines with constant clearance to give a
falling viral load. Joint models of viral and T-cell dynamics have usually allowed for T-
cell reconstitution by adding a differential equation for uninfected cells, T, with a constant
zero-order input representing T-cell production [164,166].
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ture. Antiretroviral therapy (ART) has two important PD effects. Firstly,
by interrupting the viral life cycle, it suppresses the viral load to levels
undetectable by most assays. Secondly, this reduction in the viral bur-
den allows patients' own homeostatic mechanisms to replenish the
CD4 T-cell pool. Both effects are important aims of therapy. A number
of models have been proposed for both processes, and for joint descrip-
tions of viral and T-cell responses, although most have only been ap-
plied to adult data, and very few have also incorporated drug PK.
3.1.1. Modelling viral dynamics in children
Various approaches have been taken to quantifying and modelling
viral suppression inHIV-infected children onART. The simplest pharma-
codynamic studies assess correlations between measures of drug expo-
sure (AUC, peak or trough plasma concentration) and viral suppression
(typically time to undetectable viral load, or reduction in viral load by a
speciﬁed time point). Studies of this kind were comprehensively
reviewed in 2011 by Neely and Rakhmanina [155].
More advancedmechanistic models of the virological activity of ART
predict a biphasic decay in viral load [156], andmodels of this kind have
been successfully ﬁtted in a mixed-effects framework to data from in-
fants (b2 years) starting ART [157]. This study showed no signiﬁcant
difference between the rates of viral eradication in different age groups,
but did ﬁnd faster decay in the viral load (in both phases) where chil-
dren had received a higher dose of ritonavir, the antiretroviral in
question.
3.1.2. Modelling T-cell dynamics in HIV-infected children
In some studies, investigators have ignored the role of viral suppres-
sion altogether, focussing instead on T-cell reconstitution. A simple ex-
ponential model has been employed in a mixed-effects statistical
framework to describe recovery of CD4% in HIV-infected children
starting ART, and to identify explanatory factors, which included mean
viral load on ART and age at ART initiation [158]. The same function
was applied to CD4-for-age in European and Brazilian children to con-
struct predictive models of long-term CD4 counts, given characteristics
measurable at ART initiation (again including age and viral load) [159].
Models of this typehave great potential for informing guidelines for ART
initiation and individual patientmanagement, as these children increas-
ingly survive into adulthood and long-term immunological health be-
comes a more pressing question. Finally, the same simple exponential
modelwas also used to demonstrate contrasts between recovery in chil-
dren and in adults, which are likely to be due to the importance of the
thymus and the naïve T-cell pool to children's T-cell dynamics [160].
3.1.3. Joint modelling of viral and T-cell dynamics
A number of joint models of viral and T-cell dynamics in HIV have
been developed and applied in a mixed-effects framework, many of
which use adult data.While adult models provide an important starting
point, epidemiological evidence suggests that both virological and im-
munological responses to HIV infection and ART are different in adults
and children [161]. In the simplest joint models, CD4 count and viral
load following ART initiation are described using piecewise linear
mixed-effects models, allowing correlation between random effects in
the intercepts and slopes of the viral and CD4 responses with time on
ART [162]. While not a pharmacodynamic model in the conventional
sense, this approach explores and describes the response to ART in an
empirical way while acknowledging the existence of a biological rela-
tionship. In adults, themodel identiﬁed predictors of virological and im-
munological responses to ART, and also showed that a greater decrease
in viral load was associated with better immunological response.
Most joint models of CD4 count and viral load used for population
pharmacodynamic studies have been extensions of themodel proposed
by Perelson et al. [156]. The original model described four compart-
ments: for non-infected and infected T-cells and infectious and non-
infectious virus (Fig. 2). This model has been used for parameterestimation, with population data from adults recently infected with
HIV or starting ART [163,164]. One extension of the samemodel includ-
ed a compartment for quiescent cells not liable to viral infection [165],
while another modelled a compartment of latently-infected cells
which, though infected, do not produce further virus [166].
The major strength of the Perelson-type models as a basis for
population-based statistical models is that they propose a realistic
mechanistic basis for changing viral loads and CD4 counts, such that
their parameter values quantifymeaningful biological quantities includ-
ing, importantly, drug effect. However, it is usually impossible to esti-
mate all of a model's parameters and some must be ﬁxed at values
estimated by other methods. Extensive and complete analysis of the
sensitivity of results to these assumed values is not always carried out
or fully reported, and inferencemethods do not usually quantify and de-
scribe parameter collinearities or uncertainty in model structure. This is
probably because the most obvious tools for doing so are Bayesian
methods, which are often prohibitively computationally expensive. An-
other criticism is that while this class of models impressively reproduce
dynamics in states of change— for example, immediately following HIV
infection or ART initiation— they fail to explain the slow decline in CD4
count over several years,which is characteristic of chronicHIV infection.
Thus, while they are good representations and helpful descriptions of
dynamic states, they are not able to shed light on the effects of HIV on
healthy T-cell homeostasis — effects which may be responsible for im-
portant phenomena such as incomplete T-cell reconstitution even on
long-term ART [167].
3.1.4. PKPD models of HIV infection
Mostmodelling studieswhich incorporate a drug effect onHIV and/or
CD4 dynamics do so using a single parameter which is “switched on” for
the period over which the drug is assumed to be effective [165,166].
Models incorporating pharmacokinetics are less common, and limited
mainly to theoretical rather than data-based studies [168,169]. Neverthe-
less, these models could prove very helpful in understanding the effects
of poor adherence which can be a particular issue in children because
of intolerability and social considerations.
Another interesting avenue for investigationmight be the incorpora-
tion of PK models into mechanistic models of other drug effects in HIV.
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of IL-7 therapy on CD4 T-cell survival and proliferation in HIV [170]. An-
other example is evidence that the integrase inhibitor raltegravir in-
creases production of naïve T-cells, possibly via an effect on thymic
activity, andmodellingmight also prove a productiveway to investigate
this possibility further [171].
In summary, a number of separate and joint PD models of viral and
CD4 T-cell dynamics on ART have been developed and applied to data.
Some models have incorporated a drug effect, though usually as a sim-
ple modiﬁcation of one of the parameters. There is still much scope for
the development of thesemodels by including realistic pharmacokinet-
ics and this might produce important conclusions about the effects of
planned or unplanned treatment interruptions. Recently, a joint PKPD
model including mechanistic viral dynamics, CD4 count and the PK of
each of three antiretrovirals was published on data from children aged
2 to 15 years using NLME [172]. The authors of this study were able to
separate the relative effects of each drug and develop predictivemodels
of virological failure based on individual estimates of drug inhibition
scores. The use of this approach for secondary analysis of paediatric
data already collected as part of routine care or clinical trials, could be
valuable for elucidating differences between children and adults, under-
standing immunological development in HIV and explaining differences
between individual children's responses to HIV and ART [173,174].
Models also have potential as clinical tools for predicting long-term ef-
fects of potential ART strategies and tuning drug doses [159,175].
3.2. Haematopoietic stem cell transplant
3.2.1. Introduction
Haematopoietic stem cell transplants (HSCTs) are given as treat-
ment for many immune system disorders. The stem cell source de-
ﬁnes treatment classiﬁcation, which can be either bone marrow
transplants (BMTs), peripheral blood stem cell transplants (PBSCTs)
or umbilical cord blood transplants (CBTs). A further layer of com-
plexity is added by the donors also coming in many different catego-
ries (e.g. related/unrelated, matched/unmatched). Before an HSCT, a
child will usually be given a conditioning regimen to reduce or ablate
the host immune system in order to prevent graft rejection, decrease
the incidence and severity of graft versus host disease (GvHD), and,
in the case of leukaemia, prevent relapse. The conditioning can be ra-
diotherapy, chemotherapy, anti-lymphocyte antibodies, or a mixture
of these. This leaves the patient severely immunocompromised, and
therefore vulnerable to opportunistic infections. Following HSCT,
short-term complications and long-term successful outcomes are as-
sociated with the rate and extent of recovery in the child's immune
system. Understanding the dynamics of immune reconstitution
both immediately after the HSCT and in the long term is therefore vi-
tally important. Table 2 gives an overview of the mechanism of ac-
tion and references to the PK for some drug therapies used in
conditioning and post-transplant GvHD prophylaxis. Clearly, the
multi-faceted management approach, which includes non-drug
therapies, means that linked PKPD studies of immune reconstitution
are difﬁcult to interpret. In addition to PK studies on individual
drugs, there is a parallel, almost separate literature on the PD of in-
terest: immune reconstitution post-transplant. In this section these
analyses are reviewed, together with consideration of how PKPD in
HSCT could be linked in the future.
3.2.2. Assessing immune reconstitution
Studies to date have tended to use twomethods to assess reconstitu-
tion: (1) the concentration of lymphocyte subsets at certain ﬁxed time
points after the HSCT; and (2) the time taken for lymphocyte subsets
to reach ﬁxed concentrations.
The ﬁrst method is used to assess differences in the extent of recon-
stitution. One such study found that B cell reconstitution is faster after
CBT than BMT [176]. Another found that reconstitution was fasterwithmatched sibling donors rather than familymismatched or unrelat-
ed donors [177], whilst others found T-cell reconstitution at 6 months
was signiﬁcantly delayed in patients having autologous PBSCT com-
paredwith allogeneic BMT or PBSCT [178]. A study comparing reconsti-
tution at 90 days found that unrelated CBTs had faster B-cell andNatural
Killer (NK) cell reconstitution, but delayed T-cell reconstitution when
compared to matched sibling BMTs and unrelated BMTs. They also
found that patients with consistently higher CD4 T-cell counts had a
better rate of survival [179]. A study on allogeneic HSCT patients
found at one month that younger patients reconstituted CD8 T-cells
more slowly, and that at one year measurable EBV in the blood had a
negative impact on the reconstitution of CD3 T-cells [180]. A study
assessing the effects of reduced intensity conditioning found that
there is more extensive recovery of CD3 T-cells and NK cells by four
months after HSCT compared with those given myeloablative condi-
tioning, and that therefore reduced conditioning accelerates immune
reconstitution [181].
This method is also used to ﬁnd indicators for improved long-term
survival, taking white blood cell counts above certain thresholds at cer-
tain time points. One study uses a CD4 count over 115 cells/μL at 20 days
after HSCT [182], whilst another used a CD4 count of 86 cells/μL at
35 days [177]. A study in adults used an absolute lymphocyte count of
150 cells/μL at 30 days for better non-relapse mortality and improved
survival [183]. A more sophisticated method involved forming an ellip-
soid reference domain for the normal values of a combination of three
lymphocyte subtypes, and classifying people into high- and low-risk
groups. Those in the low-risk group had a higher chance of survival
[184].
The second method is generally used to compare the rates of recon-
stitution. One study found unrelated CBT leads to faster B-cell reconsti-
tution and slower CD8 T-cell reconstitution compared with unrelated
BMT [185], while another that PBSCT led to faster reconstitution than
BMT [186]. Work looking at the effects of the conditioning drug anti-
thymocyte globulin (ATG) found that time to reach normal CD4 T-cell
counts were almost doubled in those who received ATG, but that CD8
T-cells were unaffected [187]. The high dose ATG group were also
more likely to experience life-threatening infections. Another investiga-
tion found that those who received a CBT dose high in CD45 had im-
proved reconstitution [188]. Finally, one group found a negative
correlation for CD4 T-cell reconstitution with age [185].
Some studies also use this method as an indicator for long-term sur-
vival. Research in allogeneic HSCT demonstrated that the rate of recon-
stitution of CD8 T-cells and the time to reach the 10th percentile of
normal CD4T-cell counts conditioned survival [189]; a separate analysis
showed that thosewho reconstituted to above the 5th percentile of nor-
mal CD4 T-cell counts within a year were signiﬁcantly more likely to
survive than those who never did [186].
3.2.3. The role of modelling immune reconstitution following HSCT
Whilst the approaches discussed above have sought to answer spe-
ciﬁc questions relating to the rate or extent of immune reconstitution,
mechanistic modelling in the statistical framework of NLME has the po-
tential to do both. The heterogeneity inHSCTsmeans it is difﬁcult toﬁnd
any overarching phenomena in the reconstitution, and somixed-effects
modelling could provide more informative analyses. By taking into ac-
count the inter-individual variability, caused in part by different donor
types, stem cells sources, and conditioning regimens, it is possible to
ﬁnd the fundamental determinants of the immune reconstitution.
Mechanistic modelling uses equations that represent the underlying bi-
ology and thus give biologically relevant parameters, allowing a more
meaningful covariate analysis.
CD4 T-cells can be used as an indicator for overall immune reconsti-
tution. However, modelling CD4 T-cell reconstitution in children is chal-
lenging for three reasons. (1) CD4 T-cell reconstitution is slow (taking
months to years), so the rapidly developing immune system, which re-
sults in variation of expected CD4 T-cell counts of asmuch as three-fold,
Table 2
A summary of the mechanisms of action of drugs used for conditioning and prophylaxis in HSCT patients, with references to paediatric PK studies.
Drug type Type Mode of action PK Studies
Conditioning
Fludarabine Purine analogue Interferes with ribonucleotide reductase and DNA polymerase, preventing DNA synthesis. Plunket et al. [195],
Salinger et al. [196].
Cyclophosphamide Nitrogen mustard alkylating agent Attaches alkyl group to guanine bases in DNA, thus inducing cell apoptosis. Attacks resting
and dividing cells.
Tasso et al. [197],
Van Hasselt et al. [198].
Melphalan Nitrogen mustard alkylating agent Attaches alkyl group to guanine bases in DNA, thus inducing cell apoptosis. Attacks resting
and dividing cells.
Van Hasselt et al. [198].
Busulphan Alkylating anti-neoplastic agent Alkylation causes adenine–guanine cross-links, causing cell apoptosis. Attacks resting and
dividing cells.
Van Hasselt et al. [198].
Treosulphan Alkylating anti-neoplastic agent Alkylation causes adenine–guanine cross-links, causing cell apoptosis. Attacks resting and
dividing cells. Less toxicity than with busulphan therapy.
Główka et al. [199].
Alemtuzumab Monoclonal antibody Binds to CD54, a protein found on the surface of mature lymphocytes but not on
haematopoietic stem cells.
Elter et al. [200].
Anti-thymocyte
globulin
Polyclonal antibody Rabbit derived antibodies against human T-cells, formed by injecting human lymphatic cells
into a rabbit and harvesting the antibodies produced.
Call et al. [201],
Seidel et al. [202].
Prophylaxis
Cyclosporin Immuno-suppressant Lowers immune response and activity of T-cells. Binds to lymphocyte cyclophilin, and the
resulting complex inhibits calcineurin, preventing transcription of IL-2.
Willemze et al. [203].
Methotrexate Antimetabolite Inhibits metabolism of folic acid, thereby inhibiting purine base synthesis. Mainly inhibits
rapidly proliferating cells.
Van Hasselt et al. [198].
Mycophenolate Immuno-suppressant Inhibits inosinemonophosphate dehydrogenase, the enzyme controlling the rate of synthesis
of guanine monophosphate in purine base synthesis in proliferating B- and T-cells.
Downing et al. [204].
135C.I.S. Barker et al. / Advanced Drug Delivery Reviews 73 (2014) 127–139must be taken into account [190]. (2) There is a body of evidence sug-
gesting that the thymus, where T cells are formed, has impaired func-
tion in the months after transplant [176,191–193]. (3) A model would
need to include the effects of homeostatic mechanisms for T-cells such
as competition for resources and space constraints and their effects on
cell-proliferation and cell-death rates [194]. A mechanistic model for
T-cells such as this could then form the PD element, which would be
the basis for investigating whether, and to what extent, the PK of the
drugs used in HSCT affect reconstitution.
4. Conclusions
PKPDmodelling in paediatric infectious diseases and immunology is
well-developed, in that PKPD methods have been applied in all thera-
peutic areas, albeit to varying degrees. In the case of antibacterial and
antifungal agents in particular,most studies to date have used themeth-
od of collecting PK data and then deriving dosing recommendations
based on pre-deﬁned PD targets. The potential problems with this ap-
proach are two-fold: ﬁrstly one must assume that the pre-deﬁned PD
target is applicable to the patient group studied for PK; secondly, whilst
an absolute dosemay be deﬁned, no study that we found used the PKPD
model to recommend treatment duration. Recommending an absolute
dose and duration requires the time-course of infection to be modelled
as the PD element, and this is usually not feasible in clinical studies.
More sophisticated in vitro systems which simulate multiple dose PK
proﬁles as used in the neonatal gentamicin example [47], may direct
the way to making recommendations for both dosing and duration of
treatment. In immunology, the PD endpoints are more straight-
forward to measure in the target patient groups; HIV infection, which
crosses the boundary of infectious diseases and immunology, is a
prime example of how PD models can be developed. The integration
of these mechanistic PD models with PK has begun in children [172],
and applying suchmethods for studying immune reconstitution follow-
ing HSCT and transplants indicate a potential approach towards
optimising treatment in these patients.
Acknowledgements
C.I.S.B. is funded as a Clinical Research Fellow by the Global Research
in Paediatrics — Network of Excellence (GRiP), part of the European
Union Seventh Framework Programme (FP7/2007–2013, Grant Agree-
ment number 261060).J.M.L. is funded as an Academic Clinical Fellow by the National Insti-
tute for Health Research and has received ﬁnancial support fromGilead.
J.F.S. received funding from a United Kingdom Medical Research
Council Fellowship (grant number G1002305).
References
[1] J.Y. Lee, C.E. Garnett, J.V. Gobburu, V.A. Bhattaram, S. Brar, J.C. Earp, P.R. Jadhav, K.
Krudys, L.J. Lesko, F. Li, J. Liu, R. Madabushi, A. Marathe, N. Mehrotra, C. Tornoe,
Y. Wang, H. Zhu, Impact of pharmacometric analyses on new drug approval and la-
belling decisions: a review of 198 submissions between 2000 and 2008, Clin.
Pharmacokinet. 50 (2011) 627–635.
[2] E.I. Ette, P.J. Williams, Population pharmacokinetics II: estimation methods, Ann.
Pharmacother. 38 (2004) 1907–1915.
[3] E.I. Ette, P.J. Williams, Population pharmacokinetics I: background, concepts, and
models, Ann. Pharmacother. 38 (2004) 1702–1706.
[4] E.I. Ette, P.J. Williams, J.R. Lane, Population pharmacokinetics III: design, analysis,
and application of population pharmacokinetic studies, Ann. Pharmacother. 38
(2004) 2136–2144.
[5] P.L. Bonate, Recommended reading in population pharmacokinetic pharmacody-
namics, AAPS J. 7 (2005) E363–E373.
[6] B.J. Anderson, K. Allegaert, N.H. Holford, Population clinical pharmacology of
children: general principles, Eur. J. Pediatr. 165 (2006) 741–746.
[7] B.J. Anderson, K. Allegaert, N.H. Holford, Population clinical pharmacology of
children: modelling covariate effects, Eur. J. Pediatr. 165 (2006) 819–829.
[8] M. Tod, V. Jullien, G. Pons, Facilitation of drug evaluation in children by population
methods and modelling, Clin. Pharmacokinet. 47 (2008) 231–243.
[9] G.L. Drusano, Antimicrobial pharmacodynamics: critical interactions of ‘bug and
drug’, Nat. Rev. Microbiol. 2 (2004) 289–300.
[10] R.D. Moore, P.S. Lietman, C.R. Smith, Clinical response to aminoglycoside therapy:
importance of the ratio of peak concentration to minimal inhibitory concentration,
J. Infect. Dis. 155 (1987) 93–99.
[11] D.J. Waxman, J.L. Strominger, Penicillin-binding proteins and themechanism of ac-
tion of beta-lactam antibiotics, Annu. Rev. Biochem. 52 (1983) 825–869.
[12] K.W. Bayles, The bactericidal action of penicillin: new clues to an unsolved mys-
tery, Trends Microbiol. 8 (2000) 274–278.
[13] M.P. Doogue, T.M. Polasek, Drug dosing in renal disease, the clinical biochemist,
Rev. Aust. Assoc. Clin. Biochem. 32 (2011) 69–73.
[14] T.P. Lodise, B.M. Lomaestro, G.L. Drusano, P. Society of Infectious Diseases, Applica-
tion of antimicrobial pharmacodynamic concepts into clinical practice: focus on
beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharma-
cists, Pharmacotherapy 26 (2006) 1320–1332.
[15] W.A. Craig, Basic pharmacodynamics of antibacterials with clinical applications to
the use of beta-lactams, glycopeptides, and linezolid, Infect. Dis. Clin. N. Am. 17
(2003) 479–501.
[16] M. de Hoog, J.W. Mouton, J.N. van den Anker, New dosing strategies for antibacte-
rial agents in the neonate, Semin. Fetal Neonatal. Med. 10 (2005) 185–194.
[17] A.E. Muller, J. DeJongh, Y. Bult, W.H. Goessens, J.W. Mouton, M. Danhof, J.N. van den
Anker, Pharmacokinetics of penicillin G in infants with a gestational age of less
than 32 weeks, Antimicrob. Agents Chemother. 51 (2007) 3720–3725.
[18] J. Pullen, L. de Rozario, L.M. Stolk, P.L. Degraeuwe, F.H. van Tiel, L.J. Zimmermann,
Population pharmacokinetics and dosing of ﬂucloxacillin in preterm and term ne-
onates, Ther. Drug Monit. 28 (2006) 351–358.
136 C.I.S. Barker et al. / Advanced Drug Delivery Reviews 73 (2014) 127–139[19] B.G. Charles, Y. Preechagoon, T.C. Lee, P.A. Steer, V.J. Flenady, N. Debuse, Population
pharmacokinetics of intravenous amoxicillin in very low birth weight infants, J.
Pharm. Sci. 86 (1997) 1288–1292.
[20] A.E. Muller, P.M. Oostvogel, J. DeJongh, J.W. Mouton, E.A. Steegers, P.J. Dorr, M.
Danhof, R.A. Voskuyl, Pharmacokinetics of amoxicillin in maternal, umbilical
cord, and neonatal sera, Antimicrob. Agents Chemother. 53 (2009) 1574–1580.
[21] Z. Li, Y. Chen, Q. Li, D. Cao, W. Shi, Y. Cao, D. Wu, Y. Zhu, Y. Wang, C. Chen, Popula-
tion pharmacokinetics of piperacillin/tazobactam in neonates and young infants,
Eur. J. Clin. Pharmacol. 69 (2013) 1223–1233.
[22] J.T. Zobell, C. Stockmann, D.C. Young, J. Cash, B.J. McDowell, K. Korgenski, C.M.
Sherwin, M. Spigarelli, B.A. Chatﬁeld, K. Ampofo, Population pharmacokinetic
and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate
administration in pediatric cystic ﬁbrosis patients, Clin. Ther. 33 (2011)
1844–1850.
[23] R. de Groot, B.D. Hack, A. Weber, D. Chafﬁn, B. Ramsey, A.L. Smith, Pharmacokinet-
ics of ticarcillin in patients with cystic ﬁbrosis: a controlled prospective study, Clin.
Pharmacol. Ther. 47 (1990) 73–78.
[24] M.N. Dudley, P.G. Ambrose, S.M. Bhavnani, W.A. Craig, M.J. Ferraro, R.N. Jones, C.
Antimicrobial Susceptibility Testing Subcommittee of the, I. Laboratory
Standards, Background and rationale for revised clinical and laboratory standards
institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomo-
nas aeruginosa: I. Cephalosporins and Aztreonam, Clin. Infect. Dis. Off. Publ. Infect.
Dis. Soc. Am. 56 (2013) 1301–1309.
[25] P.D. Tamma, A.E. Turnbull, A.M. Milstone, A.J. Hsu, K.C. Carroll, S.E. Cosgrove, Does
the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa in-
ﬂuence clinical outcomes of children with pseudomonal bacteremia? Clin. Infect.
Dis. 55 (2012) 799–806.
[26] C.A. Knoderer, S.A. Saft, S.G. Walker, M.D. Rodefeld, M.W. Turrentine, J.W. Brown,
D.P. Healy, K.M. Sowinski, Cefuroxime pharmacokinetics in pediatric cardiovascu-
lar surgery patients undergoing cardiopulmonary bypass, J. Cardiothorac. Vasc.
Anesth. 25 (2011) 425–430.
[27] S. Iida, T. Kawanishi, M. Hayashi, Indications for a ceftriaxone dosing regimen in
Japanese paediatric patients using population pharmacokinetic/pharmacodynamic
analysis and simulation, J. Pharm. Pharmacol. 63 (2011) 65–72.
[28] M.J. Ahsman, E.D. Wildschut, D. Tibboel, R.A. Mathot, Pharmacokinetics of cefotax-
ime and desacetylcefotaxime in infants during extracorporeal membrane oxygen-
ation, Antimicrob. Agents Chemother. 54 (2010) 1734–1741.
[29] M.L. Buck, Pharmacokinetic changes during extracorporeal membrane oxygena-
tion: implications for drug therapy of neonates, Clin. Pharmacokinet. 42 (2003)
403–417.
[30] J.S. Bradley, J.B. Sauberan, P.G. Ambrose, S.M. Bhavnani, M.R. Rasmussen, E.V.
Capparelli, Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo
simulation in the neonate, Pediatr. Infect. Dis. J. 27 (2008) 794–799.
[31] X. Du, C. Li, J.L. Kuti, C.H. Nightingale, D.P. Nicolau, Population pharmacokinetics
and pharmacodynamics of meropenem in pediatric patients, J. Clin. Pharmacol.
46 (2006) 69–75.
[32] K. Ikawa, N. Morikawa, K. Ikeda, M. Miki, M. Kobayashi, Population pharmacokinet-
ics and pharmacodynamics of meropenem in Japanese pediatric patients, J. Infect.
Chemother. 16 (2010) 139–143.
[33] J.N. van den Anker, P. Pokorna, M. Kinzig-Schippers, J. Martinkova, R. de Groot, G.L.
Drusano, F. Sorgel, Meropenem pharmacokinetics in the newborn, Antimicrob.
Agents Chemother. 53 (2009) 3871–3879.
[34] Y. Ohata, Y. Tomita, M. Nakayama, T. Kozuki, K. Sunakawa, Y. Tanigawara, Op-
timal dosage regimen of meropenem for pediatric patients based on
pharmacokinetic/pharmacodynamic considerations, Drug Metab. Pharmacokinet.
26 (2011) 523–531.
[35] H. Padari, T. Metsvaht, L.T. Korgvee, E. Germovsek, M.L. Ilmoja, K. Kipper, K.
Herodes, J.F. Standing, K. Oselin, I. Lutsar, Short versus long infusion of meropenem
in very-low-birth-weight neonates, Antimicrob. Agents Chemother. 56 (2012)
4760–4764.
[36] E.M. Parker, M. Hutchison, J.L. Blumer, The pharmacokinetics of meropenem in in-
fants and children: a population analysis, J. Antimicrob. Chemother. 36 (Suppl. A)
(1995) 63–71.
[37] P.B. Smith, M. Cohen-Wolkowiez, L.M. Castro, B. Poindexter, M. Bidegain, J.H.
Weitkamp, R.L. Schelonka, R.M. Ward, K. Wade, G. Valencia, D. Burchﬁeld, A.
Arrieta, V. Bhatt-Mehta, M. Walsh, A. Kantak, M. Rasmussen, J.E. Sullivan, N.
Finer, B.S. Brozanski, P. Sanchez, J. van den Anker, J. Blumer, G.L. Kearns, E.V.
Capparelli, R. Anand, D.K. Benjamin Jr., T. Meropenem Study, Population pharma-
cokinetics of meropenem in plasma and cerebrospinal ﬂuid of infants with
suspected or complicated intra-abdominal infections, Pediatr. Infect. Dis. J. 30
(2011) 844–849.
[38] K. Yoshizawa, K. Ikawa, K. Ikeda, H. Ohge, N. Morikawa, Population pharmacokinet-
ic–pharmacodynamic target attainment analysis of imipenem plasma and urine
data in neonates and children, Pediatr. Infect. Dis. J. 32 (2013) 1208–1216.
[39] M.L. Barclay, E.J. Begg, S.T. Chambers, Adaptive resistance following single doses of
gentamicin in a dynamic in vitro model, Antimicrob. Agents Chemother. 36 (1992)
1951–1957.
[40] M.L. Barclay, E.J. Begg, Aminoglycoside adaptive resistance: importance for effec-
tive dosage regimens, Drugs 61 (2001) 713–721.
[41] E.I. Nielsen, M. Sandstrom, P.H. Honore, U. Ewald, L.E. Friberg, Developmental phar-
macokinetics of gentamicin in preterm and term neonates: population modelling
of a prospective study, Clin. Pharmacokinet. 48 (2009) 253–263.
[42] B. Garcia, E. Barcia, F. Perez, I.T. Molina, Population pharmacokinetics of gentamicin
in premature newborns, J. Antimicrob. Chemother. 58 (2006) 372–379.
[43] J.H. Botha, M.J. du Preez, M. Adhikari, Population pharmacokinetics of gentamicin
in South African newborns, Eur. J. Clin. Pharmacol. 59 (2003) 755–759.[44] M.L. Vervelde, C.M. Rademaker, T.G. Krediet, A. Fleer, P. van Asten, A. van Dijk, Pop-
ulation pharmacokinetics of gentamicin in preterm neonates: evaluation of a
once-daily dosage regimen, Ther. Drug Monit. 21 (1999) 514–519.
[45] M. Izquierdo, J.M. Lanao, L. Cervero, N.V. Jimenez, A. Dominguez-Gil, Population
pharmacokinetics of gentamicin in premature infants, Ther. Drug Monit. 14
(1992) 177–183.
[46] P.D. Jensen, B.E. Edgren, R.C. Brundage, Population pharmacokinetics of gentamicin
in neonates using a nonlinear, mixed-effects model, Pharmacotherapy 12 (1992)
178–182.
[47] A.F. Mohamed, E.I. Nielsen, O. Cars, L.E. Friberg, Pharmacokinetic–pharmacody-
namic model for gentamicin and its adaptive resistance with predictions of dosing
schedules in newborn infants, Antimicrob. Agents Chemother. 56 (2012) 179–188.
[48] B.M. Assael, R. Parini, F. Rusconi, G. Cavanna, Inﬂuence of intrauterine maturation
on the pharmacokinetics of amikacin in the neonatal period, Pediatr. Res. 16
(1982) 810–815.
[49] H. Sardemann, H. Colding, J. Hendel, J.P. Kampmann, E.F. Hvidberg, R. Vejlsgaard,
Kinetics and dose calculations of amikacin in the newborn, Clin. Pharmacol. Ther.
20 (1976) 59–66.
[50] D.A. Kafetzis, C.A. Sinaniotis, C.J. Papadatos, J. Kosmidis, Pharmacokinetics of amikacin
in infants and pre-school children, Acta Paediatr. Scand. 68 (1979) 419–422.
[51] C.M. Sherwin, S. Svahn, A. Van der Linden, R.S. Broadbent, N.J. Medlicott, D.M. Reith,
Individualised dosing of amikacin inneonates: a pharmacokinetic/pharmacodynamic
analysis, Eur. J. Clin. Pharmacol. 65 (2009) 705–713.
[52] S. Hennig, R. Norris, C.M. Kirkpatrick, Target concentration intervention is needed
for tobramycin dosing in paediatric patients with cystic ﬁbrosis—a population
pharmacokinetic study, Br. J. Clin. Pharmacol. 65 (2008) 502–510.
[53] M. de Hoog, R.C. Schoemaker, J.W. Mouton, J.N. van den Anker, Tobramycin popu-
lation pharmacokinetics in neonates, Clin. Pharmacol. Ther. 62 (1997) 392–399.
[54] W. Lam, J. Tjon, W. Seto, A. Dekker, C. Wong, E. Atenafu, A. Bitnun, V. Waters, Y.
Yau, M. Solomon, F. Ratjen, Pharmacokinetic modelling of a once-daily dosing reg-
imen for intravenous tobramycin in paediatric cystic ﬁbrosis patients, J.
Antimicrob. Chemother. 59 (2007) 1135–1140.
[55] D.J. Touw, A.J. Knox, A. Smyth, Population pharmacokinetics of tobramycin admin-
istered thrice daily and once daily in children and adults with cystic ﬁbrosis, J. Cyst.
Fibros. 6 (2007) 327–333.
[56] J.C. Rodriguez, S. Schoenike, G.B. Scott, M.T. Rossique-Gonzalez, O.
Gomez-Marin, An evaluation of gentamicin, tobramycin, and amikacin
pharmacokinetic/pharmacodynamic parameters in HIV-infected children, J.
Pediatr. Pharmacol. Ther. 8 (2003) 274–283.
[57] R.A. Giuliano, G.A. Verpooten, L. Verbist, R.P. Wedeen, M.E. De Broe, In vivo uptake
kinetics of aminoglycosides in the kidney cortex of rats, J. Pharmacol. Exp. Ther.
236 (1986) 470–475.
[58] P.M. Tulkens, Nephrotoxicity of aminoglycoside antibiotics, Toxicol. Lett. 46 (1989)
107–123.
[59] S.J. Vandecasteele, A.S. De Vriese, E. Tacconelli, The pharmacokinetics and pharma-
codynamics of vancomycin in clinical practice: evidence and uncertainties, J.
Antimicrob. Chemother. 68 (2013) 743–748.
[60] B.J. Anderson, K. Allegaert, J.N. Van den Anker, V. Cossey, N.H. Holford, Vancomycin
pharmacokinetics in preterm neonates and the prediction of adult clearance, Br. J.
Clin. Pharmacol. 63 (2007) 75–84.
[61] M. de Hoog, R.C. Schoemaker, J.W. Mouton, J.N. van den Anker, Vancomycin popu-
lation pharmacokinetics in neonates, Clin. Pharmacol. Ther. 67 (2000) 360–367.
[62] C. Grimsley, A.H. Thomson, Pharmacokinetics and dose requirements of vancomy-
cin in neonates, Arch. Dis. Child. Fetal Neonatal Ed. 81 (1999) F221–F227.
[63] M.R. Marques-Minana, A. Saadeddin, J.E. Peris, Population pharmacokinetic analy-
sis of vancomycin in neonates. A new proposal of initial dosage guideline, Br. J. Clin.
Pharmacol. 70 (2010) 713–720.
[64] W. Zhao, E. Lopez, V. Biran, X. Durrmeyer, M. Fakhoury, E. Jacqz-Aigrain, Vancomy-
cin continuous infusion in neonates: dosing optimisation and therapeutic drug
monitoring, Arch. Dis. Child. 98 (2013) 449–453.
[65] E. Tarral, F. Jehl, A. Tarral, U. Simeoni, H.Monteil, D.Willard, J. Geisert, Pharmacokinet-
ics of teicoplanin in children, J. Antimicrob. Chemother. 21 (Suppl. A) (1988) 47–51.
[66] A. Terragna, G. Ferrea, A. Loy, A. Danese, A. Bernareggi, L. Cavenaghi, R. Rosina,
Pharmacokinetics of teicoplanin in pediatric patients, Antimicrob. Agents
Chemother. 32 (1988) 1223–1226.
[67] J.C. Lukas, G. Karikas, M. Gazouli, P. Kalabalikis, T. Hatzis, P. Macheras, Pharmacoki-
netics of teicoplanin in an ICU population of children and infants, Pharm. Res. 21
(2004) 2064–2071.
[68] S.L. Preston, G.L. Drusano, A.L. Berman, C.L. Fowler, A.T. Chow, B. Dornseif, V. Reichl,
J. Natarajan, M. Corrado, Pharmacodynamics of levoﬂoxacin: a new paradigm for
early clinical trials, JAMA 279 (1998) 125–129.
[69] J.E. Burkhardt, M.A. Hill, W.W. Carlton, J.W. Kesterson, Histologic and histochemical
changes in articular cartilages of immature beagle dogs dosed with diﬂoxacin, a
ﬂuoroquinolone, Vet. Pathol. 27 (1990) 162–170.
[70] S. Payen, R. Serreau, A. Munck, Y. Aujard, Y. Aigrain, F. Bressolle, E. Jacqz-Aigrain,
Population pharmacokinetics of ciproﬂoxacin in pediatric and adolescent patients
with acute infections, Antimicrob. Agents Chemother. 47 (2003) 3170–3178.
[71] P. Rajagopalan, M.R. Gastonguay, Population pharmacokinetics of ciproﬂoxacin in
pediatric patients, J. Clin. Pharmacol. 43 (2003) 698–710.
[72] H.G. Schaefer, H. Stass, J. Wedgwood, B. Hampel, C. Fischer, J. Kuhlmann, U.B.
Schaad, Pharmacokinetics of ciproﬂoxacin in pediatric cystic ﬁbrosis patients,
Antimicrob. Agents Chemother. 40 (1996) 29–34.
[73] P.G. Ambrose, D.M. Grasela, T.H. Grasela, J. Passarell, H.B. Mayer, P.F. Pierce, Phar-
macodynamics of ﬂuoroquinolones against Streptococcus pneumoniae in patients
with community-acquired respiratory tract infections, Antimicrob. Agents
Chemother. 45 (2001) 2793–2797.
137C.I.S. Barker et al. / Advanced Drug Delivery Reviews 73 (2014) 127–139[74] A. Forrest, D.E. Nix, C.H. Ballow, T.F. Goss, M.C. Birmingham, J.J. Schentag, Pharma-
codynamics of intravenous ciproﬂoxacin in seriously ill patients, Antimicrob.
Agents Chemother. 37 (1993) 1073–1081.
[75] H.E. Hassan, A.A. Othman, N.D. Eddington, L. Duffy, L. Xiao, K.B. Waites, D.A.
Kaufman, K.D. Fairchild, M.L. Terrin, R.M. Viscardi, Pharmacokinetics, safety, and
biologic effects of azithromycin in extremely preterm infants at risk for
ureaplasma colonization and bronchopulmonary dysplasia, J. Clin. Pharmacol. 51
(2011) 1264–1275.
[76] M. Suyagh, P.S. Collier, J.S. Millership, G. Iheagwaram, M. Millar, H.L. Halliday, J.C.
McElnay, Metronidazole population pharmacokinetics in preterm neonates using
dried blood-spot sampling, Pediatrics 127 (2011) e367–e374.
[77] M. Cohen-Wolkowiez, D. Ouellet, P.B. Smith, L.P. James, A. Ross, J.E. Sullivan, M.C.
Walsh, A. Zadell, N. Newman, N.R. White, A.D. Kashuba, D.K. Benjamin Jr., Popula-
tion pharmacokinetics of metronidazole evaluated using scavenged samples from
preterm infants, Antimicrob. Agents Chemother. 56 (2012) 1828–1837.
[78] M. Cohen-Wolkowiez, M. Sampson, B.T. Bloom, A. Arrieta, J.L. Wynn, K. Martz,
B. Harper, G.L. Kearns, E.V. Capparelli, D. Siegel, D.K. Benjamin Jr., P.B. Smith,
N. on behalf of the Best Pharmaceuticals for Children Act— Pediatric Trials, De-
termining population and developmental pharmacokinetics of metronidazole
using plasma and dried blood spot samples from premature infants, Pediatr. In-
fect. Dis. J. 32 (2013) 956–961.
[79] G.L. Kearns, S.M. Abdel-Rahman, J.L. Blumer, M.D. Reed, L.P. James, R.F. Jacobs, J.A.
Bradley, I.R. Welshman, G.L. Jungbluth, D.J. Stalker, N. Pediatric Pharmacology
Research Unit, ingle dose pharmacokinetics of linezolid in infants and children,
Pediatr. Infect. Dis. J. 19 (2000) 1178–1184.
[80] J.L. Rodriguez-Tudela, B. Almirante, D. Rodriguez-Pardo, F. Laguna, J.P. Donnelly,
J.W. Mouton, A. Pahissa, M. Cuenca-Estrella, Correlation of the MIC and dose/MIC
ratio of ﬂuconazole to the therapeutic response of patients with mucosal candidi-
asis and candidemia, Antimicrob. Agents Chemother. 51 (2007) 3599–3604.
[81] D. Andes, In vivo pharmacodynamics of antifungal drugs in treatment of candidia-
sis, Antimicrob. Agents Chemother. 47 (2003) 1179–1186.
[82] H. Saxen, K. Hoppu, M. Pohjavuori, Pharmacokinetics of ﬂuconazole in very low
birth weight infants during the ﬁrst two weeks of life, Clin. Pharmacol. Ther. 54
(1993) 269–277.
[83] D. Kaufman, R. Boyle, K.C. Hazen, J.T. Patrie, M. Robinson, L.G. Donowitz, Flucona-
zole prophylaxis against fungal colonization and infection in preterm infants, N.
Engl. J. Med. 345 (2001) 1660–1666.
[84] S.D. Kicklighter, S.C. Springer, T. Cox, T.C. Hulsey, R.B. Turner, Fluconazole for pro-
phylaxis against candidal rectal colonization in the very low birth weight infant,
Pediatrics 107 (2001) 293–298.
[85] A. Louie, Q.F. Liu, G.L. Drusano, W. Liu, M. Mayers, E. Anaissie, M.H. Miller, Pharma-
cokinetic studies of ﬂuconazole in rabbits characterizing doses which achieve peak
levels in serum and area under the concentration–time curve values which mimic
those of high-dose ﬂuconazole in humans, Antimicrob. Agents Chemother. 42
(1998) 1512–1514.
[86] L. Piper, P.B. Smith, C.P. Hornik, I.M. Cheifetz, J.S. Barrett, G. Moorthy, W.W. Hope,
K.C.Wade,M. Cohen-Wolkowiez, D.K. Benjamin Jr., Fluconazole loading dose phar-
macokinetics and safety in infants, Pediatr. Infect. Dis. J. 30 (2011) 375–378.
[87] D.Wu, K.C.Wade, D.J. Paul, J.S. Barrett, A rapid and sensitive LC–MS/MSmethod for
determination of ﬂuconazole in human plasma and its application in infants with
Candida infections, Ther. Drug Monit. 31 (2009) 703–709.
[88] J.W. Lee, N.L. Seibel, M. Amantea, P. Whitcomb, P.A. Pizzo, T.J. Walsh, Safety and
pharmacokinetics of ﬂuconazole in children with neoplastic diseases, J. Pediatr.
120 (1992) 987–993.
[89] V. Bhandari, A. Narang, B. Kumar, M. Singh, P.M. Nair, O.N. Bhakoo, Itraconazole
therapy for disseminated candidiasis in a very low birthweight neonate, J. Paediatr.
Child Health 28 (1992) 323–324.
[90] S.M. Abdel-Rahman, R.F. Jacobs, J. Massarella, R.E. Kauffman, J.S. Bradley, H.C. Kimko,
G.L. Kearns, K. Shalayda, C. Curtin, S.D.Maldonado, J.L. Blumer, Single-dose pharmaco-
kinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants,
children, and adolescents, Antimicrob. Agents Chemother. 51 (2007) 2668–2673.
[91] C. Schmitt, Y. Perel, J.L. Harousseau, S. Lemerle, E. Chwetzoff, J.P. le Moing, J.C.
Levron, Pharmacokinetics of itraconazole oral solution inneutropenic childrendur-
ing long-term prophylaxis, Antimicrob. Agents Chemother. 45 (2001) 1561–1564.
[92] A.B. Foot, P.A. Veys, B.E. Gibson, Itraconazole oral solution as antifungal prophylaxis
in children undergoing stem cell transplantation or intensive chemotherapy for
haematological disorders, Bone Marrow Transplant. 24 (1999) 1089–1093.
[93] A.H. Groll, L. Wood, M. Roden, D. Mickiene, C.C. Chiou, E. Townley, L. Dad, S.C.
Piscitelli, T.J. Walsh, Safety, pharmacokinetics, and pharmacodynamics of cyclo-
dextrin itraconazole in pediatric patients with oropharyngeal candidiasis,
Antimicrob. Agents Chemother. 46 (2002) 2554–2563.
[94] L. de Repentigny, J. Ratelle, J.M. Leclerc, G. Cornu, E.M. Sokal, P. Jacqmin, K. De
Beule, Repeated-dose pharmacokinetics of an oral solution of itraconazole in in-
fants and children, Antimicrob. Agents Chemother. 42 (1998) 404–408.
[95] D. Andes, A. Pascual, O. Marchetti, Antifungal therapeutic drug monitoring:
established and emerging indications, Antimicrob. Agents Chemother. 53 (2009)
24–34.
[96] J.M. Lestner, S.A. Roberts, C.B. Moore, S.J. Howard, D.W. Denning, W.W. Hope,
Toxicodynamics of itraconazole: implications for therapeutic drug monitoring,
Clin. Infect. Dis. 49 (2009) 928–930.
[97] W.W. Hope, E.M. Billaud, J. Lestner, D.W. Denning, Therapeutic drugmonitoring for
triazoles, Curr. Opin. Infect. Dis. 21 (2008) 580–586.
[98] A.H. Groll, G. Jaeger, A. Allendorf, G. Herrmann, R. Schloesser, V. von Loewenich, In-
vasive pulmonary aspergillosis in a critically ill neonate: case report and review of
invasive aspergillosis during the ﬁrst 3 months of life, Clin. Infect. Dis. 27 (1998)
437–452.[99] E.H. Doby, D.K. Benjamin Jr., A.J. Blaschke, R.M. Ward, A.T. Pavia, P.L. Martin, T.A.
Driscoll, M. Cohen-Wolkowiez, C. Moran, Therapeutic monitoring of voriconazole
in children less than three years of age: a case report and summary of voriconazole
concentrations for ten children, Pediatr. Infect. Dis. J. 31 (2012) 632–635.
[100] V. Kohli, V. Taneja, P. Sachdev, R. Joshi, Voriconazole in newborns, Indian Pediatr.
45 (2008) 236–238.
[101] W.W. Hope, Population pharmacokinetics of voriconazole in adults, Antimicrob.
Agents Chemother. 56 (2012) 526–531.
[102] R. Herbrecht, D.W. Denning, T.F. Patterson, J.E. Bennett, R.E. Greene, J.W. Oestmann,
W.V. Kern, K.A. Marr, P. Ribaud, O. Lortholary, R. Sylvester, R.H. Rubin, J.R. Wingard,
P. Stark, C. Durand, D. Caillot, E. Thiel, P.H. Chandrasekar, M.R. Hodges, H.T.
Schlamm, P.F. Troke, B. de Pauw, R. Invasive Fungal, Infections Group of the
European Organisation for, C. Treatment of, G. the Global Aspergillus Study,
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis,
N. Engl. J. Med. 347 (2002) 408–415.
[103] T.A. Driscoll, L.C. Yu, H. Frangoul, R.A. Krance, E. Nemecek, J. Blumer, A. Arrieta, M.L.
Graham, S.M. Bradﬁeld, A. Baruch, P. Liu, Comparison of pharmacokinetics and
safety of voriconazole intravenous-to-oral switch in immunocompromised chil-
dren and healthy adults, Antimicrob. Agents Chemother. 55 (2011) 5770–5779.
[104] T.A. Driscoll, H. Frangoul, E.R. Nemecek, D.K. Murphey, L.C. Yu, J. Blumer, R.A.
Krance, A. Baruch, P. Liu, Comparison of pharmacokinetics and safety of
voriconazole intravenous-to-oral switch in immunocompromised adolescents
and healthy adults, Antimicrob. Agents Chemother. 55 (2011) 5780–5789.
[105] M.O. Karlsson, I. Lutsar, P.A. Milligan, Population pharmacokinetic analysis of
voriconazole plasma concentration data from pediatric studies, Antimicrob. Agents
Chemother. 53 (2009) 935–944.
[106] M. Neely, T. Rushing, A. Kovacs, R. Jelliffe, J. Hoffman, Voriconazole pharmacokinet-
ics and pharmacodynamics in children, Clin. Infect. Dis. 50 (2010) 27–36.
[107] L.E. Friberg, P. Ravva, M.O. Karlsson, P. Liu, Integrated population pharmacokinetic
analysis of voriconazole in children, adolescents, and adults, Antimicrob. Agents
Chemother. 56 (2012) 3032–3042.
[108] A. Pascual, T. Calandra, S. Bolay, T. Buclin, J. Bille, O. Marchetti, Voriconazole thera-
peutic drug monitoring in patients with invasive mycoses improves efﬁcacy and
safety outcomes, Clin. Infect. Dis. 46 (2008) 201–211.
[109] G. Krishna, A. Sansone-Parsons, M. Martinho, B. Kantesaria, L. Pedicone,
Posaconazole plasma concentrations in juvenile patients with invasive fungal in-
fection, Antimicrob. Agents Chemother. 51 (2007) 812–818.
[110] R.E. Lewis, Pharmacodynamic implications for use of antifungal agents, Curr. Opin.
Pharmacol. 7 (2007) 491–497.
[111] X. Saez-Llorens, M. Macias, P. Maiya, J. Pineros, H.S. Jafri, A. Chatterjee, G. Ruiz, J.
Raghavan, S.K. Bradshaw, N.A. Kartsonis, P. Sun, K.M. Strohmaier, M. Fallon, S. Bi,
J.A. Stone, J.W. Chow, Pharmacokinetics and safety of caspofungin in neonates
and infants less than 3 months of age, Antimicrob. Agents Chemother. 53 (2009)
869–875.
[112] T.J. Walsh, P.C. Adamson, N.L. Seibel, P.M. Flynn, M.N. Neely, C. Schwartz, A. Shad,
S.L. Kaplan, M.M. Roden, J.A. Stone, A. Miller, S.K. Bradshaw, S.X. Li, C.A. Sable,
N.A. Kartsonis, Pharmacokinetics, safety, and tolerability of caspofungin in children
and adolescents, Antimicrob. Agents Chemother. 49 (2005) 4536–4545.
[113] C.C. Li, P. Sun, Y. Dong, S. Bi, R. Desai, M.F. Dockendorf, N.A. Kartsonis, A.L. Ngai, S.
Bradshaw, J.A. Stone, Population pharmacokinetics and pharmacodynamics of
caspofungin in pediatric patients, Antimicrob. Agents Chemother. 55 (2011)
2098–2105.
[114] W.W. Hope, P.B. Smith, A. Arrieta, D.N. Buell, M. Roy, A. Kaibara, T.J. Walsh, M.
Cohen-Wolkowiez, D.K. Benjamin Jr., Population pharmacokinetics of micafungin
in neonates and young infants, Antimicrob. Agents Chemother. 54 (2010)
2633–2637.
[115] W.W. Hope, N.L. Seibel, C.L. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J.J.
Keirns, D.N. Buell, T. Gumbo, G.L. Drusano, T.J. Walsh, Population pharmacokinetics
of micafungin in pediatric patients and implications for antifungal dosing,
Antimicrob. Agents Chemother. 51 (2007) 3714–3719.
[116] N.L. Seibel, C. Schwartz, A. Arrieta, P. Flynn, A. Shad, E. Albano, J. Keirns, W.M. Lau,
D.P. Facklam, D.N. Buell, T.J. Walsh, Safety, tolerability, and pharmacokinetics of
Micafungin (FK463) in febrile neutropenic pediatric patients, Antimicrob. Agents
Chemother. 49 (2005) 3317–3324.
[117] D.K. Benjamin Jr., T. Driscoll, N.L. Seibel, C.E. Gonzalez, M.M. Roden, R. Kilaru, K.
Clark, J.A. Dowell, J. Schranz, T.J. Walsh, Safety and pharmacokinetics of intrave-
nous anidulafungin in childrenwith neutropenia at high risk for invasive fungal in-
fections, Antimicrob. Agents Chemother. 50 (2006) 632–638.
[118] J.A. Dowell, W. Knebel, T. Ludden, M. Stogniew, D. Krause, T. Henkel, Population
pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, J. Clin.
Pharmacol. 44 (2004) 590–598.
[119] J.R. Starke, E.O. Mason Jr., W.G. Kramer, S.L. Kaplan, Pharmacokinetics of
amphotericin B in infants and children, J. Infect. Dis. 155 (1987) 766–774.
[120] J.M. Benson, M.C. Nahata, Pharmacokinetics of amphotericin B in children,
Antimicrob. Agents Chemother. 33 (1989) 1989–1993.
[121] J.E. Baley, C.Meyers, R.M. Kliegman, M.R. Jacobs, J.L. Blumer, Pharmacokinetics, out-
come of treatment, and toxic effects of amphotericin B and 5-ﬂuorocytosine in ne-
onates, J. Pediatr. 116 (1990) 791–797.
[122] G. Wurthwein, A.H. Groll, G. Hempel, F.C. Adler-Shohet, J.M. Lieberman, T.J. Walsh,
Population pharmacokinetics of amphotericin B lipid complex in neonates,
Antimicrob. Agents Chemother. 49 (2005) 5092–5098.
[123] Y. Hong, P.J. Shaw, C.E. Nath, S.P. Yadav, K.R. Stephen, J.W. Earl, A.J. McLachlan, Pop-
ulation pharmacokinetics of liposomal amphotericin B in pediatric patients with
malignant diseases, Antimicrob. Agents Chemother. 50 (2006) 935–942.
[124] D.W. Kimberlin, Antiviral therapies in children: has their time arrived? Pediatr.
Clin. N. Am. 52 (2005) 837–867(vii).
138 C.I.S. Barker et al. / Advanced Drug Delivery Reviews 73 (2014) 127–139[125] M. Hintz, J.D. Connor, S.A. Spector, M.R. Blum, R.E. Keeney, A.S. Yeager, Neonatal
acyclovir pharmacokinetics in patients with herpes virus infections, Am. J. Med.
73 (1982) 210–214.
[126] W.M. Sullender, A.M. Arvin, P.S. Diaz, J.D. Connor, R. Straube, W. Dankner, M.J.
Levin, S. Weller, M.R. Blum, S. Chapman, Pharmacokinetics of acyclovir suspension
in infants and children, Antimicrob. Agents Chemother. 31 (1987) 1722–1726.
[127] C.V. Fletcher, J.A. Englund, B. Bean, B. Chinnock, D.M. Brundage, H.H. Balfour Jr.,
Continuous infusion of high-dose acyclovir for serious herpesvirus infections,
Antimicrob. Agents Chemother. 33 (1989) 1375–1378.
[128] Z. Meszner, G. Nyerges, A.R. Bell, Oral acyclovir to prevent dissemination of varicel-
la in immunocompromised children, J. Infect. 26 (1993) 9–15.
[129] C. Rudd, E.D. Rivadeneira, L.T. Gutman, Dosing considerations for oral acyclovir fol-
lowing neonatal herpes disease, Acta Paediatr. 83 (1994) 1237–1243.
[130] M. Tod, F. Lokiec, R. Bidault, F. De Bony, O. Petitjean, Y. Aujard, Pharmacokinetics of
oral acyclovir in neonates and in infants: a population analysis, Antimicrob. Agents
Chemother. 45 (2001) 150–157.
[131] L. Bomgaars, P. Thompson, S. Berg, B. Serabe, A. Aleksic, S. Blaney, Valacyclovir and
acyclovir pharmacokinetics in immunocompromised children, Pediatr. Blood Can-
cer 51 (2008) 504–508.
[132] L. Zeng, C.E. Nath, E.Y. Blair, P.J. Shaw, K. Stephen, J.W. Earl, J.C. Coakley, A.J.
McLachlan, Population pharmacokinetics of acyclovir in children and young peo-
ple with malignancy after administration of intravenous acyclovir or oral
valacyclovir, Antimicrob. Agents Chemother. 53 (2009) 2918–2927.
[133] X. Saez-Llorens, R. Yogev, A. Arguedas, A. Rodriguez, M.G. Spigarelli, T. De Leon
Castrejon, L. Bomgaars, M. Roberts, B. Abrams, W. Zhou, M. Looby, G. Kaiser, K.
Hamed, Pharmacokinetics and safety of famciclovir in children with herpes sim-
plex or varicella-zoster virus infection, Antimicrob. Agents Chemother. 53 (2009)
1912–1920.
[134] J. Blumer, A. Rodriguez, P.J. Sanchez, W. Sallas, G. Kaiser, K. Hamed, Single-dose
pharmacokinetics of famciclovir in infants and population pharmacokinetic analy-
sis in infants and children, Antimicrob. Agents Chemother. 54 (2010) 2032–2041.
[135] K. Ogungbenro, I. Matthews, M. Looby, G. Kaiser, G. Graham, L. Aarons, Population
pharmacokinetics and optimal design of paediatric studies for famciclovir, Br. J.
Clin. Pharmacol. 68 (2009) 546–560.
[136] M.D. Pescovitz, B. Brook, R.M. Jindal, S.B. Leapman, M.L. Milgrom, R.S. Filo, Oral gan-
ciclovir in pediatric transplant recipients: a pharmacokinetic study, Clin. Transpl.
11 (1997) 613–617.
[137] G. Filler, D. Lampe, M.A. von Bredow, M. Lappenberg-Pelzer, S. Rocher, J. Strehlau,
J.H. Ehrich, Prophylactic oral ganciclovir after renal transplantation-dosing and
pharmacokinetics, Pediatr. Nephrol. 12 (1998) 6–9.
[138] D. Zhang, A.L. Lapeyraque,M. Popon, C. Loirat, E. Jacqz-Aigrain, Pharmacokinetics of
ganciclovir in pediatric renal transplant recipients, Pediatr. Nephrol. 18 (2003)
943–948.
[139] E. Jacqz-Aigrain, M.A. Macher, H. Sauvageon-Marthe, P. Brun, C. Loirat, Pharmaco-
kinetics of ganciclovir in renal transplant children, Pediatr. Nephrol. 6 (1992)
194–196.
[140] W. Vaudry, R. Ettenger, P. Jara, G. Varela-Fascinetto, M.R. Bouw, J. Ives, R. Walker,
W.V.S.G. Valcyte, Valganciclovir dosing according to body surface area and renal
function in pediatric solid organ transplant recipients, Am. J. Transplant. 9 (2009)
636–643.
[141] M.D. Pescovitz, R.B. Ettenger, C.F. Strife, J.R. Sherbotie, S.E. Thomas, S. McDiarmid, S.
Bartosh, J. Ives, M.R. Bouw, J. Bucuvalas, Pharmacokinetics of oral valganciclovir so-
lution and intravenous ganciclovir in pediatric renal and liver transplant recipients,
Transpl. Infect. Dis. 12 (2010) 195–203.
[142] H.E. Vezina, R.C. Brundage, T.E. Nevins, H.H. Balfour Jr., The pharmacokinetics of
valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for
Epstein–Barr virus disease, Clin. Pharmacol. Adv. Appl. 2 (2010) 1–7.
[143] S. Luck, A. Lovering, P. Grifﬁths, M. Sharland, Ganciclovir treatment in children: ev-
idence of subtherapeutic levels, Int. J. Antimicrob. Agents 37 (2011) 445–448.
[144] L.M. Frenkel, E.V. Capparelli, W.M. Dankner, J. Xu, I.L. Smith, A. Ballow, M. Culnane,
J.S. Read, M. Thompson, K.M. Mohan, A. Shaver, C.A. Robinson, M.J. Stempien, S.K.
Burchett, A.J. Melvin, W. Borkowsky, A. Petru, A. Kovacs, R. Yogev, J. Goldsmith,
E.J. McFarland, S.A. Spector, Oral ganciclovir in children: pharmacokinetics, safety,
tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group, J. Infect.
Dis. 182 (2000) 1616–1624.
[145] D.W. Kimberlin, E.P. Acosta, P.J. Sanchez, S. Sood, V. Agrawal, J. Homans, R.F. Jacobs,
D. Lang, J.R. Romero, J. Grifﬁn, G.A. Cloud, F.D. Lakeman, R.J. Whitley, A. National
Institute of, G. Infectious Diseases Collaborative Antiviral Study, Pharmacokinetic
and pharmacodynamic assessment of oral valganciclovir in the treatment of symp-
tomatic congenital cytomegalovirus disease, J. Infect. Dis. 197 (2008) 836–845.
[146] J.A. Englund, P.A. Piedra, L.S. Jefferson, S.Z. Wilson, L.H. Taber, B.E. Gilbert,
High-dose, short-duration ribavirin aerosol therapy in children with suspected re-
spiratory syncytial virus infection, J. Pediatr. 117 (1990) 313–320.
[147] A.C. Lankester, B. Heemskerk, E.C. Claas, M.W. Schilham,M.F. Beersma, R.G. Bredius,
M.J. van Tol, A.C. Kroes, Effect of ribavirin on the plasma viral DNA load in patients
with disseminating adenovirus infection, Clin. Infect. Dis. 38 (2004) 1521–1525.
[148] M. Hosoya, S. Mori, A. Tomoda, K. Mori, Y. Sawaishi, H. Kimura, S. Shigeta, H.
Suzuki, Pharmacokinetics and effects of ribavirin following intraventricular admin-
istration for treatment of subacute sclerosing panencephalitis, Antimicrob. Agents
Chemother. 48 (2004) 4631–4635.
[149] J.E. McJunkin, M.C. Nahata, E.C. De Los Reyes, W.G. Hunt, M. Caceres, R.R. Khan,
M.G. Chebib, S. Taravath, L.L. Minnich, R. Carr, C.A. Welch, R.J. Whitley, Safety and
pharmacokinetics of ribavirin for the treatment of la crosse encephalitis, Pediatr.
Infect. Dis. J. 30 (2011) 860–865.
[150] R.P. Gonzalez-Peralta, D.A. Kelly, B. Haber, J. Molleston, K.F. Murray, M.M. Jonas, M.
Shelton, G. Mieli-Vergani, Y. Lurie, S. Martin, T. Lang, A. Baczkowski, M. Geffner, S.Gupta, M. Laughlin, C.T.G. International Pediatric Hepatitis, Interferon alfa-2b in
combination with ribavirin for the treatment of chronic hepatitis C in children: ef-
ﬁcacy, safety, and pharmacokinetics, Hepatology 42 (2005) 1010–1018.
[151] J. Oxford, Oseltamivir in themanagement of inﬂuenza, Expert. Opin. Pharmacother.
6 (2005) 2493–2500.
[152] J.F. Standing, M. Tsolia, I. Lutsar, Pharmacokinetics and pharmacodynamics of
oseltamivir in neonates, infants and children, Infect. Disord. Drug Targets 13
(2013) 6–14.
[153] D.W. Kimberlin, E.P. Acosta, M.N. Prichard, P.J. Sanchez, K. Ampofo, D. Lang, N.
Ashouri, J.A. Vanchiere, M.J. Abzug, N. Abughali, M.T. Caserta, J.A. Englund, S.K.
Sood, M.G. Spigarelli, J.S. Bradley, J. Lew, M.G. Michaels, W. Wan, G. Cloud, P.
Jester, F.D. Lakeman, R.J. Whitley, A. National Institute of, G. Infectious Diseases
Collaborative Antiviral Study, Oseltamivir pharmacokinetics, dosing, and resistance
among children aged b2 years with inﬂuenza, J. Infect. Dis. 207 (2013) 709–720.
[154] N. Sugaya, S. Kohno, T. Ishibashi, T. Wajima, T. Takahashi, Efﬁcacy, safety, and phar-
macokinetics of intravenous peramivir in children with 2009 pandemic H1N1 in-
ﬂuenza A virus infection, Antimicrob. Agents Chemother. 56 (2012) 369–377.
[155] M.N. Neely, N.Y. Rakhmanina, Pharmacokinetic optimization of antiretroviral ther-
apy in children and adolescents, Clin. Pharmacokinet. 50 (2011) 143–189.
[156] A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho, HIV-1 dynamics
in vivo: virion clearance rate, infected cell life-span, and viral generation time, Sci-
ence 271 (1996) 1582–1586.
[157] P. Palumbo, H. Wu, E. Chadwick, P. Ruan, K. Luzuriaga, J. Rodman, R. Yogev,
A.C.T.G.I. Pediatric, Virologic response to potent antiretroviral therapy and model-
ing of HIV dynamics in early pediatric infection, J. Infect. Dis. 196 (2007) 23–29.
[158] P. De Beaudrap, F. Rouet, P. Fassinou, A. Kouakoussui, S. Mercier, R. Ecochard, P.
Msellati, CD4 cell response before and after HAART initiation according to viral
load and growth indicators in HIV-1-infected children in Abidjan, Cote d'Ivoire, J.
Acquir. Immune Deﬁc. Syndr. 49 (2008) 70–76.
[159] J. Lewis, A.S. Walker, H. Castro, A. De Rossi, D.M. Gibb, C. Giaquinto, N. Klein, R.
Callard, Age and CD4 count at initiation of antiretroviral therapy in HIV-infected
children: effects on long-term T-cell reconstitution, J. Infect. Dis. 205 (2012)
548–556.
[160] J. Lewis, A.S. Walker, N. Klein, R. Callard, CD31+ cell percentage correlation
with speed of CD4+ T-cell count recovery in HIV-infected adults is reversed
in children: higher thymic output may be responsible, Clin. Infect. Dis. 55
(2012) 304–307(author reply 307).
[161] H.I.V.E.R.E.S.G. Collaboration of ObservationalC.A. Sabin, C.J. Smith, A. d'Arminio
Monforte, M. Battegay, C. Gabiano, L. Galli, S. Geelen, D. Gibb, M. Guiguet, A.
Judd, C. Leport, F. Dabis, N. Pantazis, K. Porter, F. Rafﬁ, C. Thorne, C. Torti, S.
Walker, J. Warszawski, U. Wintergerst, G. Chene, J. Lundgren, Response to combi-
nation antiretroviral therapy: variation by age, Aids 22 (2008) 1463–1473.
[162] R. Thiebaut, H. Jacqmin-Gadda, S. Walker, C. Sabin, M. Prins, J. Del Amo, K. Porter, F.
Dabis, G. Chene, C. Collaboration, Determinants of response to ﬁrst HAART regimen
in antiretroviral-naive patients with an estimated time since HIV seroconversion,
HIV Med. 7 (2006) 1–9.
[163] J. Drylewicz, D. Commenges, R. Thiebaut, Score tests for exploring complexmodels:
application to HIV dynamics models, Biom. J. 52 (2010) 10–21.
[164] H. Putter, S.H. Heisterkamp, J.M. Lange, F. de Wolf, A Bayesian approach to param-
eter estimation in HIV dynamical models, Stat. Med. 21 (2002) 2199–2214.
[165] J. Guedj, R. Thiebaut, D. Commenges, Maximum likelihood estimation in dynamical
models of HIV, Biometrics 63 (2007) 1198–1206.
[166] M. Lavielle, A. Samson, A. Karina Fermin, F. Mentre, Maximum likelihood estima-
tion of long-term HIV dynamic models and antiviral response, Biometrics 67
(2011) 250–259.
[167] C.F. Kelley, C.M. Kitchen, P.W. Hunt, B. Rodriguez, F.M. Hecht, M. Kitahata, H.M.
Crane, J. Willig, M. Mugavero, M. Saag, J.N. Martin, S.G. Deeks, Incomplete periph-
eral CD4+ cell count restoration in HIV-infected patients receiving long-term anti-
retroviral treatment, Clin. Infect. Dis. 48 (2009) 787–794.
[168] L. Rong, A.S. Perelson, Modeling latently infected cell activation: viral and latent
reservoir persistence, and viral blips in HIV-infected patients on potent therapy,
PLoS Comput. Biol. 5 (2009) e1000533.
[169] O. Krakovska, L.M. Wahl, Drug-sparing regimens for HIV combination therapy:
beneﬁts predicted for “drug coasting”, Bull. Math. Biol. 69 (2007) 2627–2647.
[170] D.J. Thiébaut R, C. Lacabaratz, J.D. Lelievre, G. Chêne, S. Beq, T. Croughs, D.
Commenges, J.F. Delfraissy, Y. Levy, In vivo quantiﬁcation of the effect of IL-7 on
proliferation, survival and production of CD4+ T cells: mathematical analysis of
one phase I study in HIV-1 infected patients, Conference Poster at Systems Ap-
proaches in Immunology, 2010, (Santa Fe, NM, USA).
[171] C. Garrido, N. Rallon, V. Soriano, M. Lopez, N. Zahonero, C. de Mendoza, J.M. Benito,
Mechanisms involved in CD4 cell gains in HIV-infected patients switched to
raltegravir, Aids 26 (2012) 551–557.
[172] N. Bouazza, J.M. Treluyer, P. Msellati, P. Van de Perre, S. Diagbouga, B. Nacro, H.
Hien, E. Zoure, F. Rouet, A. Ouiminga, S. Blanche, D. Hirt, S. Urien, A novel pharma-
cokinetic approach to predict virologic failure in HIV-1-infected paediatric pa-
tients, Aids 27 (2013) 761–768.
[173] Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Chil-
dren. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,
Available at http://aidsinfo.nih.gov/contentﬁles/lvguidelines/pediatricguidelines.
pdf(Last accessed 30th June 2013).
[174] P.S. Committee, S. Welch, M. Sharland, E.G. Lyall, G. Tudor-Williams, T. Niehues, U.
Wintergerst, T. Bunupuradah, M. Hainaut, M. Della Negra, M.J. Pena, J.T. Amador,
G.C. Gattinara, A. Compagnucci, A. Faye, C. Giaquinto, D.M. Gibb, K. Gandhi, S.
Forcat, K. Buckberry, L. Harper, C. Konigs, D. Patel, D. Bastiaans, PENTA 2009 guide-
lines for the use of antiretroviral therapy in paediatric HIV-1 infection, HIVMed. 10
(2009) 591–613.
139C.I.S. Barker et al. / Advanced Drug Delivery Reviews 73 (2014) 127–139[175] M. Prague, D. Commenges, J. Drylewicz, R. Thiebaut, Treatment monitoring of
HIV-infected patients based on mechanistic models, Biometrics 68 (2012)
902–911.
[176] E. Charrier, P. Cordeiro, R.M. Brito, S. Mezziani, S. Herblot, F. Le Deist, M. Duval, Re-
constitution of maturating and regulatory lymphocyte subsets after cord blood and
BMT in children, Bone Marrow Transplant. 48 (2013) 376–382.
[177] M. Berger, O. Figari, B. Bruno, A. Raiola, A. Dominietto, M. Fiorone, M. Podesta, E.
Tedone, S. Pozzi, F. Fagioli, E. Madon, A. Bacigalupo, Lymphocyte subsets recovery
following allogeneic bone marrow transplantation (BMT): CD4+ cell count and
transplant-related mortality, Bone Marrow Transplant. 41 (2008) 55–62.
[178] W. Schwinger, D. Weber-Mzell, B. Zois, T. Rojacher, M. Benesch, H. Lackner, H.J.
Dornbusch, P. Sovinz, A. Moser, G. Lanzer, K. Schauenstein, P. Ofner, R.
Handgretinger, C. Urban, Immune reconstitution after puriﬁed autologous and al-
logeneic blood stem cell transplantation comparedwith unmanipulated bonemar-
row transplantation in children, Br. J. Haematol. 135 (2006) 76–84.
[179] I.H. Bartelink, S.V. Belitser, C.A. Knibbe, M. Danhof, A.J. de Pagter, T.C. Egberts, J.J.
Boelens, Immune reconstitution kinetics as an early predictor for mortality using
various hematopoietic stem cell sources in children, Biol. Blood Marrow Trans-
plant. 19 (2013) 305–313.
[180] H.O. Kim, H.J. Oh, J.W. Lee, P.S. Jang, N.G. Chung, B. Cho, H.K. Kim, Immune recon-
stitution after allogeneic hematopoietic stem cell transplantation in children: a sin-
gle institution study of 59 patients, Korean J. Pediatr. 56 (2013) 26–31.
[181] X. Chen, G.A. Hale, R. Barﬁeld, E. Benaim, W.H. Leung, J. Knowles, E.M. Horwitz, P.
Woodard, K. Kasow, U. Yusuf, F.G. Behm, R.T. Hayden, S.A. Shurtleff, V. Turner,
D.K. Srivastava, R. Handgretinger, Rapid immune reconstitution after a
reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem
cell graft for paediatric refractory haematological malignancies, Br. J. Haematol.
135 (2006) 524–532.
[182] R. Fedele, M. Martino, C. Garreffa, G. Messina, G. Console, D. Princi, A. Dattola, T.
Moscato, E. Massara, E. Spiniello, G. Irrera, P. Iacopino, The impact of early CD4+
lymphocyte recovery on the outcome of patients who undergo allogeneic bone
marrow or peripheral blood stem cell transplantation, Blood Transfus. 10 (2012)
174–180.
[183] S.K. Tedeschi, M. Jagasia, B.G. Engelhardt, J. Domm, A.A. Kassim, W. Chinratanalab,
S.L. Greenhut, S. Goodman, J.P. Greer, F. Schuening, H. Frangoul, B.N. Savani, Early
lymphocyte reconstitution is associated with improved transplant outcome after
cord blood transplantation, Cytotherapy 13 (2011) 78–82.
[184] M. Koenig, S. Huenecke, E. Salzmann-Manrique, R. Esser, R. Quaritsch, D.
Steinhilber, H.H. Radeke, H. Martin, P. Bader, T. Klingebiel, D. Schwabe, G.
Schneider, T. Lehrnbecher, A. Orth, U. Koehl, Multivariate analyses of immune re-
constitution in children after allo-SCT: risk-estimation based on age-matched leu-
kocyte sub-populations, Bone Marrow Transplant. 45 (2010) 613–621.
[185] C. Renard, V. Barlogis, V. Mialou, C. Galambrun, D. Bernoux, M.P. Goutagny, L.
Glasman, A.D. Loundou, F. Poitevin-Later, F. Dignat-George, V. Dubois, C. Picard,
C. Chabannon, Y. Bertrand, G. Michel, Lymphocyte subset reconstitution after un-
related cord blood or bone marrow transplantation in children, Br. J. Haematol.
152 (2011) 322–330.
[186] U. Koehl, K. Bochennek, S.Y. Zimmermann, T. Lehrnbecher, J. Sorensen, R. Esser, C.
Andreas, C. Kramm, H.P. Gruttner, E. Falkenberg, A. Orth, P. Bader, D. Schwabe, T.
Klingebiel, Immune recovery in children undergoing allogeneic stem cell trans-
plantation: absolute CD8+ CD3+ count reconstitution is associated with survival,
Bone Marrow Transplant. 39 (2007) 269–278.
[187] M. Duval, B. Pedron, P. Rohrlich, F. Legrand, A. Faye, B. Lescoeur, P. Bensaid, R.
Larchee, G. Sterkers, E. Vilmer, Immune reconstitution after haematopoietic trans-
plantation with two different doses of pre-graft antithymocyte globulin, Bone
Marrow Transplant. 30 (2002) 421–426.
[188] V. Barlogis, L. Glasman, C. Brunet, A.D. Loundou, C. Lemarie, C. Galambrun, I. Thuret,
C. Curtillet, M. Le Meignen, F. Bernard, H. Chambost, B. Calmels, C. Picard, C.
Chabannon, F. Dignat-George, G. Michel, Impact of viable CD45 cells infused onlymphocyte subset recovery after unrelated cord blood transplantation in children,
Biol. Blood Marrow Transplant. 17 (2011) 109–116.
[189] R. Giannelli, M. Bulleri, M. Menconi, G. Casazza, D. Focosi, S. Bernasconi, C. Favre,
Reconstitution rate of absolute CD8+ T lymphocyte counts affects overall survival
after pediatric allogeneic hematopoietic stem cell transplantation, J. Pediatr.
Hematol. Oncol. 34 (2012) 29–34.
[190] S. Huenecke, M. Behl, C. Fadler, S.Y. Zimmermann, K. Bochennek, L. Tramsen, R.
Esser, D. Klarmann, M. Kamper, A. Sattler, D. von Laer, T. Klingebiel, T.
Lehrnbecher, U. Koehl, Age-matched lymphocyte subpopulation reference values
in childhood and adolescence: application of exponential regression analysis,
Eur. J. Haematol. 80 (2008) 532–539.
[191] H. Olkinuora, E. von Willebrand, J.M. Kantele, O. Vainio, K. Talvensaari, U.
Saarinen-Pihkala, S. Siitonen, K. Vettenranta, The impact of early viral infections
and graft-versus-host disease on immune reconstitution following paediatric
stem cell transplantation, Scand. J. Immunol. 73 (2011) 586–593.
[192] E. Clave, M. Busson, C. Douay, R. Peffault de Latour, J. Berrou, C. Rabian, M.
Carmagnat, V. Rocha, D. Charron, G. Socie, A. Toubert, Acute graft-versus-host dis-
ease transiently impairs thymic output in young patients after allogeneic hemato-
poietic stem cell transplantation, Blood 113 (2009) 6477–6484.
[193] P.R. Fallen, L. McGreavey, J.A. Madrigal, M. Potter, M. Ethell, H.G. Prentice, A.
Guimaraes, P.J. Travers, Factors affecting reconstitution of the T cell compartment
in allogeneic haematopoietic cell transplant recipients, Bone Marrow Transplant.
32 (2003) 1001–1014.
[194] C.D. Surh, J. Sprent, Homeostasis of naive andmemory T cells, Immunity 29 (2008)
848–862.
[195] W. Plunkett, V. Gandhi, P. Huang, L.E. Robertson, L.Y. Yang, V. Gregoire, E. Estey, M.J.
Keating, Fludarabine: pharmacokinetics, mechanisms of action, and rationales for
combination therapies, Semin. Oncol. 20 (1993) 2–12.
[196] D.H. Salinger, D.K. Blough, P. Vicini, C. Anasetti, P.V. O'Donnell, B.M. Sandmaier, J.S.
McCune, A limited sampling schedule to estimate individual pharmacokinetic pa-
rameters of ﬂudarabine in hematopoietic cell transplant patients, Clin. Cancer.
Res. 15 (2009) 5280–5287.
[197] M.J. Tasso, A.V. Boddy, L. Price, R.A. Wyllie, A.D. Pearson, J.R. Idle, Pharmacokinetics
and metabolism of cyclophosphamide in paediatric patients, Cancer Chemother.
Pharmacol. 30 (1992) 207–211.
[198] J.G. van Hasselt, N.K. van Eijkelenburg, J.H. Beijnen, J.H. Schellens, A.D. Huitema,
Optimizing drug development of anti-cancer drugs in children using modelling
and simulation, Br. J. Clin. Pharmacol. 76 (2013) 30–47.
[199] F.K. Glowka, M. Karazniewicz-Lada, G. Grund, T. Wrobel, J. Wachowiak, Pharmaco-
kinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based pre-
parative regimen for allogeneic haematopoietic SCT, Bone Marrow Transplant. 42
(Suppl. 2) (2008) S67–S70.
[200] T. Elter, I. Molnar, J. Kuhlmann, M. Hallek, C. Wendtner, Pharmacokinetics of
alemtuzumab and the relevance in clinical practice, Leuk. Lymphoma 49 (2008)
2256–2262.
[201] S.K. Call, K.A. Kasow, R. Barﬁeld, R. Madden, W. Leung, E. Horwitz, P. Woodard, J.C.
Panetta, S. Baker, R. Handgretinger, J. Rodman, G.A. Hale, Total and active rabbit
antithymocyte globulin (rATG; Thymoglobulin) pharmacokinetics in pediatric pa-
tients undergoing unrelated donor bone marrow transplantation, Biol. Blood Mar-
row Transplant. 15 (2009) 274–278.
[202] M.G. Seidel, G. Fritsch, S. Matthes-Martin, A. Lawitschka, T. Lion, U. Potschger, A.
Rosenmayr, G. Fischer, H. Gadner, C. Peters, Antithymocyte globulin pharmacoki-
netics in pediatric patients after hematopoietic stem cell transplantation, J. Pediatr.
Hematol. Oncol. 27 (2005) 532–536.
[203] A.J. Willemze, S.C. Cremers, R.C. Schoemaker, A.C. Lankester, J. den Hartigh, J.
Burggraaf, J.M. Vossen, Ciclosporin kinetics in children after stem cell transplanta-
tion, Br. J. Clin. Pharmacol. 66 (2008) 539–545.
[204] H.J. Downing, M. Pirmohamed, M.W. Beresford, R.L. Smyth, Paediatric use of myco-
phenolate mofetil, Br. J. Clin. Pharmacol. 75 (2013) 45–59.
